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 ABSTRACT 
 
Antitumor Activity of Antimalarials  in Human Breast Cancer Cells 
 
 
Qun Zhou 
Previously we showed that quinidine arrested MCF-7 cells in G1 phase of the cell cycle and led to a 
G1 to G0 transition followed by apoptotic cell death (Wang et al., 1998). The present experiments 
demonstrate that MCF-7, MCF-7ras, T47D, MDA-MB-231, and MDA-MB-435 cells transiently 
differentiate before undergoing apoptosis in response to quinidine. The cells accumulated lipid droplets 
and the cytokeratin 18 cytoskeleton was reorganized. Hyperacetylated histone H4 appeared within 2 h 
of the addition of quinidine to the medium, and levels were maximal by 24 h.  Quinidine treated MCF-
7 cells showed elevated p21/WAF1, hypophosphorylation and suppression of retinoblastoma protein, 
and down-regulation of cyclin D1. Quinidine did not show evidence for direct inhibition of histone 
deacetylase enzymatic activity in vitro.  HDAC-1 was undetectable in MCF-7 cells 30 min after 
addition of quinidine to the growth medium. The proteasome inhibitors, MG-132  and lactacystin 
completely protected HDAC-1 from the action of quinidine. These data demonstrate that quinidine is a 
breast tumor cell differentiating agent that causes the loss of HDAC-1 via a proteasomal sensitive 
mechanism. Moreover, to determine whether effects of quinidine on cell differentiation and apoptosis 
is generalizable to quinoline antimalarials, we tested typical quinoline antimalarial drugs for their 
ability to  regulate MCF-7 cell differentiation, hyperacetylation histone H4 and apoptosis. MTS IC50 
of amodiaquin, chloroquine, halofantrine, primaquine, quinidine as well as quinine induced 
hyperacetylation of histone H4 without inhibiting HDAC activity. These results indicate that an 
alkylamino-substituted antimalarial ring might be important for acetylation of histone H4. 
Accumulation of lipid droplets was observed in cells treated with chloroquine, primaquine, quinidine 
and quinine. Only MTS IC50 of chloroquine and quinidine increased p21(WAF1) protein levels and  
apoptosis. The data imply that p21(WAF1) might play a determining role in  apoptosis in MCF-7 cells 
treated with antimalarials. Chloroquine was most active in stimulating MCF-7 apoptosis, and quinine 
was most active in promoting MCF-7 cell differentiation. We conclude that distinct mechanisms are 
responsible for breast tumor cell differentiation and activation of apoptosis by quinoline antimalarials. 
Alkylamino-substituted antimalarial ring compounds represented by quinidine, quinine and 
chloroquine will be useful model compounds in the search for more active breast tumor differentiating 
agents. 
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1. Breast Cancer Therapy 
     Breast cancer is the most commonly diagnosed invasive malignancy and a leading cause (after lung 
cancer) of cancer deaths in American women (Greenlee et al., 2000). Most women succumb to breast 
cancer when their cancers metastasize; long-term survival depends on if the cancer remains localized.  
The approach to control this malignancy has made significant strides during the last decades of the 20th 
century.  Surgical removal of the primary tumor in patients can reduce breast cancer mortality (Early 
Breast cancer Trialists’ Collaborative Group, 1995); radiation therapy techniques and adjuvant 
systemic therapy can delay or prevent recurrence and thereby improve survival rates (Hortobagyi, et 
al.,  2000). 
 
1.1. Surgical Therapy 
 
    The primary goal of cancer surgery is the complete eradication of local and regional tumor. 
Traditionally, axillary lymph node dissection (ALND) has been considered as a standard part of the 
surgical management of patients with breast cancer, which provides accurate prognosis information, 
maintains local control of disease in the axilla and provides a rational basis for decision about adjuvant 
therapy (Sakorafas, 2000). Recently, there has been increased interest in extending the local treatment 
of breast cancer to “incision-less surgery”. The idea is to destroy all the tissue in a radius around the 
tumor while leaving the remaining breast unaltered using different energy sources such as laser for 
interstitial hyperthermia (Feyerabend, et al., 1996 ). This approach has been used in number of patients 
who are diagnosed with as a small, local and single focus of infiltrating ductal breast carcinoma 
(Feyerabend, et al., 1996). 
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1.2. Irradiation Therapy 
 
     The objective of radiation treatment of the patient with breast cancer is eradication of the tumor 
with preservation of the structure and function of normal tissues. For radiation therapy, as for surgery, 
this means local-regional control of tumor cells, implying also a careful pretreatment evaluation and 
long-term post-treatment observation. 
     One radiation treatment is external beam radiotherapy, which is very effective when treating 
localized disease by reducing the tumor bulk, so reducing the amount of dying tissue and the 
possibility for infection and odor (Regnard,  et al., 1998). The challenge for radiotherapy is for more 
radiosensitivity that is a measure of the susceptibility to cellular injury by ionizing radiation. 
Mammalian cells vary in their radiosensitivity as they progress through the mitotic division cycle 
(Sullivan, et al.,1980). In general, G0 and late S-phase cells are most resistant, and late G2 and mitotic 
(M) cells are the most sensitive (Sullivan, et al.,1980). Following irradiation with 4-8 Gy (gray), MCF-
7 human breast cancer cells exhibit transient delay in progression from G1 into S phase (Nagasawa et 
al., 1998). The use of combination radiation therapy and chemotherapy have increased strikingly over 
the past few years. Radiation therapy is directed at the primary tumor masses and regional nodes, 
whereas chemotherapeutic agents may modify the response of tumor and normal tissues to irradiation. 
It has been reported that cytotoxic drugs that are S-phase-specific could synergize with radiation 
therapy to overcome radioresistance in the S phase (Sondel et al., 1986).  
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1.3. Adjuvant Therapy 
 
    There are two major types of systemic therapy: cancer chemotherapy and biological therapy 
(immunotherapy). There is considerable overlap between these two types of therapy, and they are 
increasingly employed together in various combinations (Trail  et al., 1993). 
Chemotherapy involves the use of cytotoxic drugs and hormones to induce tumor cell death. The 
typical chemotherapeutical agents include cyclophosphamide, doxorubicin, methotrexate and 
tamoxifen 
      Cyclophosphamide is used to treat a wide range of human malignancies. Bioactivation of 
cyclophosphamide yields 4-hydroxycyclophosphamide , which then interconverts with its tautomer 
aldophosphamide. Through an elimination mechanism, aldophosphamide fragments to acrolein and 
phosphoramide mustard (PM) (Anderson et al., 1995). It has been reported that PM and acrolein are 
reactive species toward DNA. The covalent DNA adducts formed by PM are intra/interstand cross-link 
DNA adducts and mono adducts at the N position of guanine (Anderson et al., 1995). The DNA 
adducts from PM and acrolein have been found in rodents after administration of cyclophosphamide 
(Hemminki 1985). The alkylating agent cyclophosphamide is a potent immunosuppressive drug that 
has been synthesized. The proliferating lymphoid cells are primarily targeted by this agent. It is a 
known carcinogen and is associated with induction of therapy-related leukemia and bladder cancer 
(Ortiz  et al., 1992). In vivo genotoxic activity including chromosome aberrations, sister chromatid 
exchange, and gene mutation has been reported in both animals and humans after administration of 
cyclophosphamide (Anderson et al., 1995).  
      Doxorubicin is considered one of the most active drugs in breast cancer, with response rates of 
40% when given as a first-line single agent (Houstone et al., 1993). This drug is capable of binding to 
DNA, usually by interposition between base pairs with subsequent uncoiling of the DNA helix. 
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Intercalation impairs DNA synthesis and RNA synthesis which inhibit tumor cell proliferation 
(Houstone et al., 1993). 
     Methotrexate (MTX) is one of the most commonly used agents in the treatment of solid 
malignancies as well as leukemias and lymphomas. However, the toxicities of MTX to bone marrow 
and gastrointestinal tract accompany this therapy (Moscow 1998).  This drug is a member of the 
antifolate class of compounds that exerts its cytotoxicity by blocking DNA/RNA synthesis pathways, 
MTX  binds to the active catalytic site of dihydrofolate reductase (DHFR), and blocks the synthesis of 
the reduced form of folate that acts as a one-carbon unit donor in biochemical syntheses. Lack of this 
cofactor interrupts the biosynthesis of thymidylate and purine nucleotides, thereby interfering with the 
formation of DNA and RNA (Moscow 1998).  
Endocrine Therapy is an effective treatment for breast cancer patients.  Normally, estrogens function 
by binding to estrogen receptor. Subsequent to ligand (estrogen)-ER binding, ligand-ER complexes 
undergo conformation change, dissociate from the chaperone heat shock protein Hsp90 and become 
active complexes (Hurd  and Moudgil 1998). In the nucleus, ER-ligand complexes bind to a 
transcriptional complex and an estrogen response element on DNA (Beato et al., 1996). Recent 
evidence suggests that the activated ligand-ER complexes participate a switching between binding of a 
multisubunit co-repressor complex containing factors (not completely identified yet) with histone 
deacetylase activity (HDAC) and binding of a co-activator complex containing factors, SRC (steroid 
receptor co-activators)/NcoA (nuclear receptor co-activators), with histone acetylase activity (HAT) 
such as p300/CBP(CREB (cyclic AMP-responsive element binding)-binding protein) and PCAF 
(p300/CBP- associated factor)(Grunstein 1997). Ligand-ER binding results in the replacement of the 
repressor complex, by a co-activator SRC-1/NcoA-1 complex with multiple HAT proteins which 
catalyze  histone  acetylation (Torchia et al, 1998).  The net effect is that estrogen activates gene 
expression and increases cell proliferation (Katzenellenbogen, 1997).  
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     In about one-third of advanced breast cancers, estrogens stimulate tumor growth, whereas estrogen 
deprivation causes tumor regression. Inhibition of estrogenic stimulation is the main target in 
endocrine treatment of breast cancer. This is achieved by either blocking the estrogen receptor or the 
inhibition of estrogen production. 
     Tamoxifen (TAM) is a typical agent for hormone therapy, which binds to estrogen receptors, 
competes with endogenous estrogens, and occludes the coactivator association between the activation 
function domain 2 (AF2) and the receptor ligand-binding domain (LBD), leading to inhibition of  
tumor cell growth (Shiau  et al., 1998). Inhibition of ER by TAM blocks the secretion of polypeptide 
growth factors such as epidermal growth factor and transforming growth factor , leading to growth 
arrest of ER-positive cells (Taylor  et al., 1984). In addition to its cytostatic effects mediated through 
the ER in ER-positive MCF-7 cells, TAM delays G1 cell cycle transit leading to an accumulation of 
non-dividing cells in G0/G1 phase (Sutherland, et al., 1983). The cell cycle delay is ER-independent, 
since TAM also inhibits the growth of the ER-negative cell line BT20 by accumulation of cells in the 
G0/G1 phase (Osborne et al., 1989). TAM cytotoxicity is proposed to be mediated by the induction of 
apoptosis (Perry  et al., 1995). 
     A doxorubicin based chemotherapy combined with tamoxifen proved superior to tamoxifen alone 
(Fisher  et al., 1990). This finding was supported by in vitro studies. Clinical studies suggest an 
additive or even synergistic effect of doxorubicin and tamoxifen, especially in postmenopausal women, 
where addition of tamoxifen to chemotherapy increases the recurrence-free survivability in breast 
cancer patient. This benefit is more pronounced for ER positive patients than for ER negative ones 
(Osborne  et al., 1989). 
     Femara (letrozole). Aromatase is an enzyme that catalyzes the conversion of the androgens 
androstenedione and testosterone to estrone and estradiol. The cytochrome P-450 enzyme complex 
aromatase is the main target for inhibition of estrogen biosynthesis. In recent years, several new 
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aromatase inhibitors including Femara have been developed.  Femara is the selective aromatase 
inhibitor and recently licensed by the FDA for advanced breast cancer treatment in postmenopausal 
women where tamoxifen therapy has failed (Harvey  1998). It is a potent inhibitor of cell proliferation 
and more effective than tamoxifen in MCF-7 cells (Brodie et al., 1998). 
Immunotherapy involves the use of biological molecules known as biological modifiers. The HER2 
receptor is the protein product of protooncogene HER2 (also known as neu and as c-erbB-2), and is a 
member of EGFR (epidermal growth factor receptor) family of transmembrane tyrosine kinases. Upon 
binding of ligand to the EGFR, HER2 is recruited as the preferred partner of these ligand-bound 
receptors into an active, phosphorylated heterodimeric complex that activates several signaling 
pathways involved in the proliferation and survival of breast cancer cells (Riese et al., 1998). 
Overexpression of HER2 in breast cancer patients is associated with poor prognosis (Riese et al., 
1998). 
    HER2 has been proposed to contribute to antiestrogen-resistance because tumors expressing high 
levels of HER2 exhibit lower clinical response rates after antiestrogen therapy (Houston  1999).  
HER2-overexpressing estrogen receptor positive breast cancer cells failed to respond to tamoxifen 
(Elledge  et al., 1998).  HER2 overexpression activates the MAPK (mitogen-activated protein kinase) 
signaling pathway, which causes phosphorylation of  ER, and ligand-independent ER activation with 
loss of the inhibitory effect of tamoxifen (Bunone  et al., 1996). Immunotherapy using a monoclonal 
antibody against HER2, has proved to be clinically efficacious in breast cancer patients (Baselga   et 
al., 1996). Herceptin, an antibody against HER2, increased the inhibitory effect of tamoxifen against 
HER2 overexpressed BT-474 human breast cancer cells in culture (Witters et al., 1997). Herceptin 
targets the HER2 ectodomain and blocks HER2 cleavage preventing the production of an active 
truncated HER2 fragment (Molina  et al., 2001). Treatment with herceptin and doxorubicin showed 
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greater inhibition of cell proliferation than that observed with any agent alone in BT-474 cells (Baselga  
et al., 1998).  
    Summary.  Adjuvant therapy has led to a reduction in the risk of relapse of only 20-40%, depending 
on the chemotherapeutic agents used (Hortobagyi et al., 2000). Frequent toxic effects, including 
nausea, vomiting and alopecia, are usually connected with adjuvant therapies.  In addition, the 
emergence of multidrug resistance poses a considerable obstacle to success of breast cancer 
chemotherapy. Therefore, the development of new target-selective ‘smart’ drugs that are less toxic and 
circumvent drug resistance, is an important goal.  
 
2. Antimalarials 
      Malaria is the common devastating human infection in the developing countries.  There are nearly 
2.5 million deaths each year (Phillips 2001). The human malaria parasites have P.falciparum, P.vivax, 
P.ovale and P.malariae species (Galinski et al., 1996). Much of human mortality is caused by infection 
with P. falciparum (Phillips 2001). Although this mosquito-born infection has been eradicated from 
the USA, immigration from and travel to endemic regions still cause health problems.  
     The asexual erythrocytic cycle produces more merozites that are released with the destruction of the 
red blood cell after 48 or 72 h; for the human malaria parasites, depending on the species, merozites 
then immediately invade additional erythrocytes (Hawking et al., 1968). For the past 50 years, 
quinoline-containing drugs have been the  main class of antimalarial agents in use. In most cases, these 
agents are targeted at the asexual erythrocytic stage of the parasite. The quinoline-containing drugs 
include the cinchona alkaloids which are quinine and quinidine, the aminoalcohol quinine analogue 
mefloquine, halofantrine, primaquine, chloroquine and its relative amodiaquin (White 1994). 
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2.1. Antimalarial drugs  
    The structures of quinoline antimalarials are shown in Figure1.  Most of the aminoquinoline 
compounds behave like quinine in many respects, but each drug has individual properties. 
     Quinidine has a quinoline group through a secondary alcohol linkage to a quinuclidine ring.  A 
vinyl side chain is attached to the quinuclidine ring while a methoxy side chain is linked to the 
quinoline ring. Quinine has the same structure as quinidine except for the steric configuration of the 
secondary alcohol group. Quinidine is more potent as an antimalarial and more toxic than quinine. It 
has been reported that quinine inhibits incorporation of adenosine into parasitic DNA, whereas the 
mechanism by which quinidine acts as an antimalarial  is not known (Whinstanley et al., 1993).  
      Mefloquine is a 4-quinolinemethanol derivative that has four optional isomers with about the same 
antimalarial potency. Melfloquine is selective against mature trophozoite and schizont forms of 
malarial parasites. The exact mechanism of action of mefloquine is unknown. It does not intercalate 
with DNA (Davidson  et al., 1997). 
       Chloroquine is a 4-alkylamino substituted quinoline that also possesses a chlorine substitution at 
the 7-position of the ring. Chloroquine is a more potent antimalarial than either quinidine or quinine, 
but despite chloroquine’s structural similarities with quinine and quinidine, chloroquine has a different 
mechanism of antimalarial activity, and chloroquine-resistant malaria responds to quinine treatment 
(White, et al., 1994). Chloroquine’s antimalarial action is mediated through binding to a Hb 
(hemoglobin) degradation product which becomes toxic to the parasite. It selectively inhibits haem 
polymerization which is an essential defense mechanism to detoxify haem (Wellems, et al., 1992).  
       Amodiaquin  is a analog of chloroquine, which is no longer used  as an antimalarial because its use 
increases  hepatic toxicity and agranulocytosis (White et al., 1994). 
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       Primaquine is a quinoline derivative that is synthesized with methoxy and substituted 8-amino 
groups.  The great clinical value of primaquine  is  active against the primary exoerythrocytic forms of 
P. falciparum. The  8-aminoquinolines exert  the most potent antimalarial effect (Tarlov et al., 1962). 
      Halofantrine   The (+) and (-) enantiomers of halofantrine are equally active against malaria (Carrol 
et al., 1978).  Halofantrine acts against the asexual erythrocytic stage of Plasmodium; it is primarily 
used as an alternative to quinidine and mefloquine to treat acute malarial attacks caused by 
chloroquine-resistant and multidrug-resistant strains of P.falciparum (Basco  et al., 1992). Halofantrine 
also acts on parasite mitochondria to form toxic complexes, which destroy biomembranes (Warhurst et 
al., 1987). 
2.2. Cancer Treatment by Antimalarials 
      In the past twenty years, the potential of antimalarial drug such as chloroquine to improve cancer 
therapy has been investigated. Chloroquine treatment (20mg/ml) in cultured mouse myeloid leukemia 
M1 cells for 4 days induced differentiation, inhibited DNA and RNA polymerases, and interfered with 
lysosomal function (Takenaga, et al. 1980; Morrow, et al., 1989). Chloroquine inhibited cell 
proliferation in a dose and time-dependent manner in malignant B cells obtained from a patient with B-
cell chronic lymphocytic leukaemia, and induced apoptosis as demonstrated by a decrease in the 
amount of bcl-2 protein, increased caspase-3 activation and DNA fragmentation (Lagneaux et al., 
2001).   
     Chloroquine also acts as an effective potentiator of hyperthermia, which is an adjunctive treatment 
modality in neural crest tumors such as melanoma and murine neuroblastoma (Morrow, et al., 1989; 
Thomas 1990). In C3H/He mice bearing transplantable mammary adenocarcinomas (C3HBA), 5-
fluorouracil (5-FU) and chloroquine phosphate  increased complete remissions compared with 5-FU 
treatment alone (Shoemaker, et al., 1978; Shoemaker, et al., 1979).  Chloroquine therapy also 
enhanced radiosensitization in patients with chest wall necrosis; the acute radiation reaction was also 
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greater in chloroquine treated animals (Utley, et al., 1997). Moreover, chloroquine was used to reduce 
the toxicity of the anti-brain tumor drug TFCRM107 by selectively suppressing toxicity to the 
vasculature without altering the antitumor efficacy (Hagihara et al., 2000).  
     Chloroquine increased the effect of Aluminium Chloride Phthalocyanine (ALCIPc), a second 
generation sensitizer for the photodynamic therapy of EMT-6 mouse mammary tumor cells. In the 
photodynamic cancer therapy model, ALCIPc was incorporated together and formed the  polymeric 
micelles by dialysis. Chloroquine, a weak base, raised the internal pH of acidic organelles such as the 
lysosome. Endosomal lysosomal acidity is important for the pH-sensitive polymeric micelles to be 
fully effective (cytotoxicity) (Taillefer, et al., 2001).  Chloroquine  and its analogues  have the potential 
for enhancing the efficient  gene transfer  into various gynecological tumors by their  endosomal 
buffering capacity, therefore  these compounds are also used in gene therapy applications (Keil, et al., 
2001). Interestingly, chloroquine and its derivative hydroxychloroquine have been reported to possess 
anti-HIV-1 activity in lymphocytic and monocytic cells. The anti-HIV effect by chloroquine has been 
confirmed in vivo in two clinical trials (Boelaert et al., 2001). Combination therapy with the 
antimalarial agent chloroquine may be an interesting option for treatment for cancer and HIV infected 
individuals in the developing countries. 
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Quinoline (QL)
Quinine (QN) Quinidine (QD)
Quinolinic Acid (QA)
Mefloquine (MQ) Halofantrine (HF)
Primaquine (PQ)
Chloroquine (CL)
Amodiaquin (AQ)
Figure. 1.  Chemical Structures of Antimalarials
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3. Mechanism for Regulating Tumor Cell Growth 
 
 
      The cell cycle is regulated by the sequential activation of cyclin-dependent kinases (CDKs). The 
activation of CDKs and subsequent phosphorylation of specific substrates govern progress through the 
cell cycle on multiple levels (Figure 2). CDKs are inactive in the absence of cyclin binding; therefore, 
cyclin abundance is a major determinant of cyclin-CDK activity (Sherr 1996). Each cyclin is typically 
present for only a restricted portion of the cell cycle, and changes in cyclin abundance are sufficient to 
alter the rate of cell cycle progression (Hunter et al., 1994). Specific CDK-inhibitory (CKI) proteins 
including p15,  p16, p21(WAF1/cip1) and p27 target CDK4 that associates with the D-type cyclins in 
G1 phase. The cyclin-dependent kinase inhibitor p21(WAF1) causes cell arrest in G1 through 
inhibition of CDK complexes, which are required for the G1 to S transition (Xiong  et al. 1993). 
p21(WAF1) may have additional roles in cell cycle and cancer, because it is able to inhibit DNA 
replication and repair, independently of its ability to inhibit CDK activity (Michieli et al., 1994). It has 
been reported that p21(WAF1) may play a role in the differentiation of epithelial cells and act as a 
tumor-suppressor gene (Halevy  et al., 1995 and Chen  et al,  1995).  p21(WAF1) immunoreactivity 
has been recently observed in human neoplastic tissues, where its expression is related to cell 
proliferation and differentiation (Doglioni  et al.,  1996).  High p21(WAF1) expression could be related 
to normal or increased p53 function, and low p21(WAF1) expression could be related to p53 gene 
deletion or mutation.  p21(WAF1) expression may reflect different p53 functional states.  This idea is 
based on the observation that p21(WAF1) expression in human breast cancer is low when p53 is 
mutated (Bukholm et al.,  1997). 
     One of the key endogenous substrates of CDK4 in G1 phase is the retinoblastoma protein (Rb). Its 
phosphorylation is an important step in the transition between the G1 and S phases of the cell cycle 
because sufficiently phosphorylated Rb releases a transcription factor E2F1 that drives cells into S 
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phase (Slansky  et al., 1996 ).  A diverse body of evidence now indicates that pRb stands in the midst 
of G1/S cell cycle regulatory pathway that suffers disruption during the pathogenesis of very many 
human tumors. Disruption of the pRb/E2F1 interaction could be achieved by pRb functional 
inactivation, viral oncoprotein binding, or CDK phosphorylation during tumor progression. As a direct 
consequence, E2F1 is liberated from control and the progression of cells into late G1 and S becomes 
uncontrolled. Therefore, drugs which restore pRb normal function are potential antitumor agents. 
 
4. Ubiquitin-mediated Protein Degradation 
 
    Endogenous proteins are selectively targeted by the ubiquitin/proteasome system for degradation by 
means of a complex system of protein-protein recognition elements. Degradation of a protein via 
proteasomes occurs by two distinct and successive steps. First, the protein is conjugated to ubiquitin. In 
the second step, the 26S proteasome recognizes the ubiquitin-conjugated protein, and degrades it. The 
ubiquitin system is in both cytosolic and  nuclear, and has high selectivity for normal short-lived 
proteins and misfolded proteins (Kisselev, et al., 1999). Many cell cycle regulatory proteins, including 
p27 and c-myc have been shown to be phosphorylated, ubiquitinated, and degraded by the proteasome 
(Montagnoli et al., 1999; Gregory  et al., 2000). Thus, the activity of the proteasome performs an 
important cell cycle regulatory function. 
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Figure 2.  Cell Cycle Regulatory Proteins for G1 to S  Phase
Transition. Rb (retinoblastoma); CKI (cyclin dependent kinase
inhibitor); CDK (cyclin dependent kinase); p (phosphorylation).
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M
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5. Apoptosis 
 
    Apoptosis or programmed cell death is a major mechanism for maintaining cell homeostasis in 
normal development and adult life. It is also an important determinant of the response of tumors to 
chemotherapeutic agents. Morphological features of apoptosis include chromatin condensation, cell 
shrinkage, nuclear fragmentation and blebbing with the formation of membrane-bound apoptotic 
bodies. These events are the result of complex cellular biochemical pathways (Vaux et al., 1999). 
Disregulation of apoptosis has been identified in many human diseases and is recognized as an 
important event during carcinogenesis and in tumor progression. Thus, manipulation of apoptotic 
pathways is a promising approach for the treatment of various human cancers.  
     Activation of caspases is a central mechanism of apoptosis. Caspases are a family of cysteine 
proteases, which cleave specific substrates using a cysteine-aspartate recognition sequence. Caspases 
are synthesized as pro-enzymes and are activated by internal cleavage. Caspases are the executioners 
of cell death. 
     Apoptosis usually involves the release of cytochrome c from mitochondria by many different 
stimuli including tumor necrosis factor (TNF), chemotherapeutic and DNA-damaging agents (Reed  
1997). Chemotherapeutic-induced cytochrome c release is caspase-independent in contrast to TNF, 
which is receptor-mediated apoptosis and depends on activation of caspase-8 (Sun  et al., 1999). 
Activation of cytochrome c-caspase-9 pathway by chemotherapeutic agents leads to tumor cell 
apoptosis (Brown et al., 1999, and Tada-Oikawa et al., 1998).  In the cytosol, cytochrome c combines 
with Apaf-1 in the presence of ATP to activate caspase-9, which in turn activates effector caspases 
such as caspase-3,-6 and –7 (Zou et al.,  1997; Green  et al.,  1998). The activation of caspase-3 and 
subsequent degradative events are responsible for many of the biochemical and morphological changes 
associated with the apoptotic phenotype including DNA cleavage (Sun  et al., 1999). Defects in this 
pathway which suppress apoptosis may contribute significantly to the development of breast cancer 
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and resistance to chemotherapeutic agents. Chemotherapeutic resistance represents a major limitation 
in the ability of chemotherapy to cure cancer. Alteration in apoptotic-associated genes are often 
associated with chemotherapeutic resistance (Fisher 1994). The tumor suppressor genes p53 and pRb, 
the key regulators in DNA damage-induced apoptosis, are frequently mutated in human tumors (Thor  
et al; 1992). Overexpression of anti-apoptotic Bcl-2 family members has been detected in primary 
tumors and tumor cell lines (Lotem et al., 1993). Recently, loss of caspase-3 owing to 47-base pair 
deletion within exon 3 of the caspase-3 gene in MCF-7 cells has been reported (Reiner et al., 1998). 
Mutated caspase-3 leads to a block in DNA fragmentation of MCF-7 cells (Reiner et al., 1998). 
Caspase-3 deficiency is believed to contribute to chemotherapeutic resistance in many cancer cell lines 
(Prokop  et al.,  2000). Correction of these alterations could result in sensitization of the defective cells 
to chemotherapeutic agents (Bargou  et al.,  1996).  
 
6. Histone Deacetylase (HDAC) 
     DNA is highly organized and packaged into the nucleus in eukaryotes (Wolffe 1995). This 
packaging and organization are achieved by DNA and DNA binding proteins including histones which 
form a complex structure referred to as chromatin. An average of 150 base pairs of DNA wrapped 
around a histone octamer, comprised of  histones H2A, H2B, H3 and H4 forms the basic structural unit 
of the chromatin, the nucleosome (Kornberg  1974).  Each nucleosome contains two H2As, two H2Bs, 
two H3s, and two H4s in the core. Linker histone H1 appears to lie on the outer portion of the 
nucleosome. Repeating nucleosomes are assembled into a higher order chromatin structure.  
     Nucleosomes have both positive and negative effects on transcription (Durrin et al., 1991). The 
dynamic effects of nucleosomes on transcription may be due, in part, to the acetylation of lysine 
residues present in the hydrophilic amino-terminal portions (tails) of the core histones (Turner, 1991 
and Davie  et al., 1998). This acetylated state is maintained through the competing activities of histone 
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acetyltransferases (HAT) and deacetylases (HDAC). HAT transfers the acetate from acetyl-CoA to 
neutralize the positively charged--amino group of an unacetylated lysine residue. In contrast, 
deacetylation is achieved through the hydrolysis of the acetyl moiety, restoring a positive charge 
(Jeppesen  et al., 1993). There is a general correlation between core histone acetylation and gene 
activity. Conversely, histone hypoacetylation leads to transcriptional repression. 
       To date, at least nine different mammalian HDACs were described, which are classified in to class 
I, class II, and Sir2 family. The class I proteins (HDAC1, HDAC2 and HDAC3) are homologou to the 
yeast transcriptional regulator Rpd3, bind to E2F and repress transcription through an association with  
pRb (Taunton, et al., 1996; Brehm, et al., 1998); the class II proteins (HDAC4, HDAC5, and HDAC6) 
are homologou to yeast HDA1 and form a second family of deacetylases that are specifically involved 
in cell differentiation (Verdel,  et al., 1999; Grozinger, et al., 1999). The class II  proteins localize to 
distinct nuclear bodies within the cell nucleus and  only recently have  been shown to interact with 
SMRT (silencing mediator for retinoid and thyroid receptor)/N-CoR (nuclear receptor corepressor) as 
result of transcriptional repression. TSA  completely disrupted these nuclear bodies (Kao, et al., 2000).  
The Sir2 family depends on nicotinamide-adenine dinucleotide (NAD) (Imai, et al., 2000). Specific 
roles for these enzymes and their target genes remain to be clarified. Inhibition of HDAC activity 
results in the accumulation of acetylated histones H2a, H2b, H3, and H4. As a result of HDAC 
inhibition, rather specific effects occur upon the transcription of a small subset of the genome (Van 
Lint, 1996). Evidence provided by DNA microarrays using malignant cell lines cultured with a HDAC 
inhibitor showed that a small (1-2%) number of gene products is altered (Van Lint et al., 1996). 
      In MCF-7 cells, histone deacetylase 1 (HDAC1) is the most abundant enzyme in HDAC family and 
is mainly located in nuclear matrix (Hendzel et al., 1991).  Histone H4 is the primary target of HDAC1 
enzymatic activity (Chen et al., 1999), and this histone undergoes acetylation at lysine residues at 
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multiple sites within the histone tails extending from the histone octamer of the nucleosome core 
(Davie et al., 1998). 
 6.1. Disruption of HAT and /or HDAC activity and development of cancer 
     Recent evidence suggests a relationship between alteration in chromatin structure by histone 
hyperacetylation or deacetylation and the development of cancer (Archer et al., 1999). Human CBP 
participates as a coactivator in cyclic-AMP-regulated gene expression.  Mutations in the CBP gene  
affect HAT activity,  and are associated with leukemogenesis (Yang et al., 1996; Petrij  et al., 1995). 
One of the functions of pRb is to recruit HDAC1 and suppress E2F activity, but the pRb pathway of 
G1-S cell cycle control is aberrantly altered in most cancers (Archer, et al., 1999). HDAC inhibitors 
have therapeutic potential because of their ability to elevate histone acetylation level and perhaps 
restore normal growth control upon tumor cells. Pharmacological inhibitors of HDAC modulate 
transcription, induce differentiation, and cause cancer cell apoptosis (Marks et al., 2000).  
6.2. Pharmacological HDAC Inhibitors 
 
     Histone deacetylase inhibitors such as sodium butyrate (NaB), trapoxin (TPX), and trichostatin A 
(TSA), increase acetylated histones in many cell types (Yoshida et al., 1995). Unlike NaB which also 
has nonselective effects, TSA is thought to specifically inhibit HDAC (Kijima et al. 1993). For this 
reason, TSA has been used as a tool to study the consequences of histone acetylation in vivo or in vitro 
(Ogryzko  et al., 1996).  
     The molecular structures for TPX and TSA are shown in Figure 3.  The functional group of TSA 
responsible for the inhibition of HDAC is the hydroxamic acid moiety (Yoshida  et al.,1990), which 
chelates  the zinc ion in the active-site pocket of HDAC. TPX contains an epoxyketone structure at the 
end of the side chain of a constituent amino acid. The epoxyketone function group inserts and binds to  
the pocket of  HDAC, leading to the  irreversible inhibition of HDAC (Kijima   et al., 1993). 
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    The characteristic cell response to HDAC inhibitors includes cell cycle arrest in G1, elevated 
p21(WAF1) expression, hypophosphorylation of pRb, hyperacetylation of histones H4, cell 
differentiation and apoptosis (Yoshida  et al., 1995; Sambucetti et al., 1999). Histone hyperacetylation 
by NaB and TSA is directly linked to the activation of p21(WAF1/Cip1) transcription by Sp1 and/or 
Sp3 transcription factor activation, which occurs in a p53-independent manner (Xiao et al., 1999). 
HDAC inhibitors such as TSA also synergize with retinoic acid to enhance differentiation of myeloid 
leukemia HL-60 cells (Janson  1997).  
     TSA demonstrated antiproliferative actions in a number of tumor cell lines. TSA has been  named 
as a transcriptional therapeutic agent for neoplasia (Kosugi  et al.,1999). A big concern of  
transcriptional therapy with TSA is its toxicity. Svensson et al. (1998) reported that TSA treatment in 
vitro caused malformation in embryos. However, a systematic analysis of the toxicology of TSA in 
adult mice and during embryonic development showed that TSA was not toxic to mouse embryos, and 
did not intervene with postnatal development (Nervi  et al., 2001). Therefore, TSA might be a nontoxic  
or minimal toxic HDAC inhibitor for the transcriptional therapy of neoplasia. Most recently, FK228, 
(Nakajima  et al., 1998), a synthetic HDAC inhibitor with antitumor activity, is under going clinical 
trial (phase I) at the National Cancer Institute (Frederick, MD) for cancer therapy. 
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TPX
TSA
Figure 3.  Structures of TPX and TSA
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6.3. Drug Resistance and HDAC Inhibitors 
     The chemotherapeutic agents are challenged by both intrinsic drug resistance and the development 
of acquired drug resistance during breast cancer treatment (Drewinko,  et al., 1981). At the molecular 
level, at least three protein systems have been reported to be involved in drug resistance: the glucose-
regulated protein (grp), the P-glycoprotein (Pgp), and the heat shock protein (hsp).  
    Cell stress conditions, such as glucose starvation, can be associated with drug resistance. Glucose-
starved stress condition is not observed in normal tissues. This tumor specific condition commonly 
causes the glucose-regulated stress response of cancer cells (Shen, et al., 1987).  Induction of grp leads 
to an increase in resistance to multiple anticancer drugs, such as doxorubicin, etoposide, and 
vincristine (Wallner et al, 1986; Shen, et al., 1987; Hughes, et al., 1989). The mechanism by which grp 
induces drug resistance is not clear.  However, in mammalian cells the grps represent a subset of 
stress-induced proteins that were not associated with heat shock and thermotolerance (Shen, et al., 
1987).  
      The second system implicated in drug resistance is the transmembrane Pgp encoded by the MDR 
(multidrug resistance) gene family (Gottesman, et al., 1988). Composed of two members (MDR1 and 
MDR2), only MDR1 seems to be functionally linked to development of the MDR phenotype 
(Roninson, et al., 1986). The acquisition of the MDR phenotype, defined as increased resistance 
against cytotoxic drugs, represents one of the major obstacles for chemotherapy of tumors and 
malignancies.  One of the mechanisms that may account for MDR is the surface accumulation of Pgp. 
Pgp is involved in the transport of small molecules and mediates the efflux of drugs from cells, which 
is called the multidrug transporter (Germann  et al., 1993). The MDR1 gene  is subject to control by a 
variety of internal and external stimuli, including differentiation signals, hsp, cytokines, hormones and 
a variety of toxic insults (Ince et al., 1997). MDR1 mRNA levels are increased by heat shock, sodium 
arsenite, and cadmium chloride treatment but not by stresses that activate grp expression (Chin et al., 
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1990). Tumor cells that overexpress Pgp are resistant to a wide range of caspase-dependent apoptotic 
inducers (Smyth  et al., 1998); thus, new approaches to inhibit Pgp protein expression are needed and 
are clinically important.   
     Overexpression of Pgp can be circumvented by interrupting the transcriptional activation  of the 
MDR1 gene.  The proximal promoter of MDR1 contained several regulatory regions, including an 
inverted CCAAT box at –82 to –73 and a GC element at –56 to –42, both of which have been shown to 
be required for constitutive promoter activity (Jin,  et al., 1998).  Binding of Sp1  to the GC element 
activates the MDR1 promoter in Drosophila cells (Cornwell,  et al., 1993), while interaction of the 
trimeric transcription factor NF-Y with the CCAAT box has been implicated in constitutive regulation 
of the MDR1 promoter in several cell lines ( Goldsmith, et al., 1993; Jin, et al.,  1998).  Recent studies 
have shown that the MDR1 gene can be more activated by HDAC inhibitors such as sodium butyrate 
(NaB), TSA and differentiating agents (Jin  et al., 1998; Abolhoda  et al.,1999).  These agents 
stimulated the histone acetytransferase PCAF to bind with the MDR1 promoter as result of  
acetylattion of promoter-proximal histones following transcriptional activation (Mickley, et al, 1989; 
Jin, et al., 1998;  Hu  et al., 2000). The net effect needs to be determined; it is possible that Pgp protein 
function is blocked by TSA and NaB treatment.  
       The third stress-responsive system implicated in drug resistance is the heat shock protein system. 
Resistance to doxorubicin has been observed in human breast cancer cells with elevated hsp27.  MDA-
MB-231 human breast cancer cells transfected with a plasmid containing the structural gene for human 
hsp27 expressed both thermoresistance and drug resistance (Oesterreich, et al.,1993). Hsp27 could be a 
very important mediator of chemoresistance. 
 
 
 
 24 
Program Aims 
 
    Quinidine is used as an anti-malarial and also as an anti-arrhythmic agent. Previous studies from our 
laboratory demonstrated that quinidine arrested cells in early G1 phase, and induced apoptosis in 
MCF-7 cells (Wang  et al., 1998), but the biochemical mechanisms for the anti-proliferative effects of 
quinidine are not well understood. To clarify the molecular mechanisms of the anti-proliferative 
activity of quinidine, we investigated the effects of quinidine on cell cycle regulatory proteins and 
histone acetylation . Based on effects of quinidine, a prototype quinoline derivative, on HDAC activity, 
histone H4 and apoptosis, we begin to explore whether all quinoline-based antimalarials  have a similar 
profile of antitumor activities in human breast cancer cells.  
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1. Chemicals 
     Amodiaquin, chloroquine, etoposide, Oil  Red O, quinidine, quinine, quinoline,  quinolinic acid, 
and trichostatin A (TSA) were purchased from Sigma Chemical Company (St. Louis, MO). Calcium 
acetate was purchased from Fisher (Pittsburgh, PA). Mefloquine and Halofantrine Methylsulfate were 
provided by the National Cancer Institute (Bethesda, MD). Recombinant histone H4 protein 
(expression in E.coli, cat #14-412) was purchased from Upstate Biotechnology (Lake Placid, NY). 
 
2.Tissue Culture 
       Permanent cell lines derived from patients with breast carcinomas were used in these studies.  
MCF-7 cells, passage numbers 30 – 50, were maintained in Dulbecco’s Modified Eagle’s medium 
(DMEM) (BioWhittaker, Walkersville, MD) supplemented with 10% fetal bovine serum (FBS) 
(Hyclone Laboratories, Inc., Logan, Utah), and 40 ug/ml gentamicin. MCF-7-YAMA cells were 
obtained from Dr. Lahti (St. Jude’s Children’s Research Hospital, Memphis, TN). The cells were 
stably transformed with a plasmid expressing caspase-3. MCF-7 –YAMA cells were grown in DMEM 
supplemented with 10% FBS, and 500ug/ml geneticin.  MDA-MB-468 cells were from the American 
Type Culture Collection (Rockville, MD). MDA-MB-468 cells lines were maintained in medium 
consisting of DMEM/F12 (1:1) (Life Technologies, Rockville, MD) supplemented with 10% FBS, and 
50units/ml of both penicillin and streptomycin. The cells were maintained at 37C in a humidified 
atmosphere of 93% air/7% CO2. After 4 or 5 days, cells became about 70-80% confluent and were 
passaged at a 1:5 ratio.  
 
3. Western Blotting 
      Confluent  cells were subcultured (1x106) in 100mm2 dishes. Twelve hours after plating, cells were 
treated with drug. At specific time points, cell lysates were prepared according to Dr. J.R Davie’s 
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protocol (personal communication). The cells were harvested at the times indicated by scraping into 
harvesting buffer (1% SDS and 10mM Tris-HCl, pH 7.4).  Cell lysates were boiled for 5 min,   
centrifuged in an Eppendorf microcentrifuge (14,000 rpm, 5 minutes) at 4qC, and then  the supernatants 
were collected. One tablet CompleteTM (protease inhibitor cocktail, cat. # 1836153, Roche Boehringer 
Mannheim, Indianapolis, IN) was dissolved in 1.5 ml distilled H2O; 2.5% (v/v) of reconstituted 
protease inhibitor solution was added immediately to the supernatant. The protein concentration of the 
supernatant was determined using a BCA protein assay (Pierce, Rockford, IL) and bovine serum 
albumin as a standard unless otherwise noted. For Western blots, 5x SDS (sodium dodecyl sulfate)-
loading buffer (3.15mM Tris-HCl, pH 7.0, 50%(v/v) glycerol, 0.1% SDS (w/v), and 1% (v/v) 
bromphenol blue) plus 2-mercaptoethanol (12.5ul of 2-mercaptoethanol per 100 ul 5x SDS-loading 
buffer)  was added to the protein samples. The protein samples were heated in a sand bath for 5 min at 
1000C.  Equal amounts of protein were loaded onto 10% SDS-polyacrylamide mini-gels. Colored 
molecular weight protein markers (RPN756, Amersham Pharmacia Biotech Inc., Piscataway, NJ) were 
used to indicate different protein molecular weight. Proteins were transferred to polyvinylidene 
difluoride membranes (PVDF, Novex, San Diego, CA) and blocked overnight at 4 0C using 3% nonfat 
milk blocking buffer (3g non-fat dry milk in 100 ml of TBS (20 mM Tris-HCl, pH 7.5, 0.5M NaCl) 
and 0.05% (v/v) Tween 20).  Membranes were incubated for 3 h at room temperature with the 
following primary antibodies: mouse monoclonal anti-p21 (WAF1) (Ap-1, cat. # OP64-100UG) from 
Calbiochem (Cambridge, MA), mouse monoclonal anti-epithelial glycoprotein (cat. # MAB-4043) 
from Chemicon International (Temecula, CA) and anti-acetylated histone H4 antibody (rabbit 
polyclonal, cat.# 06-598, Upstate Biotechnology, NY).  The primary antibodies were diluted 1:500 in 
Western washing solution (0.1% non-fat dry milk, 0.1% albumin (chicken egg), 1% (v/v) FBS, 
10%(v/v)10xPBS (1.4 M NaCl, 0.02 M KCl, 0.08 M Na2HPO4.7H2O and 15 mM KH2PO4, pH 7.0) and 
0.2%(v/v) Tween-20). After washing three times with Western washing solution and then one time 
 28 
with TBS, the antigen-antibody complexes were incubated 1h at room temperature with HRP 
(horseradish peroxidase)-conjugated secondary antibodies (rabbit IgG-HRP (SC-2004), and mouse 
IgG-HRP (SC-2005) from Santa Cruz Biotechnology) diluted 1:3000 in Western washing solution. 
After washing three times with TBS, antibody binding was visualized using enhanced 
chemiluminescence (SuperSignal West Pico, cat. #1856136, Pierce, Rockford, IL) and 
autoradiography. The experiments were repeated at least three times.   
 
4. Histone extraction  
    Confluent  MCF-7 cells  were plated at 6x106 (maximal cell number: 1x107) /T-162 flask in  20 ml 
of 5% FBS/DMEM. The cells then were grown in a humidified incubator chamber in 7% CO2 at 370 C 
for 12 h. MTS IC50 of each antimalarial was added into each flask and incubated for the times 
indicated. After that, the growth medium  was removed. Following a quick rinse with ice-cold PBS, 
cells were scraped into 4 ml of ice-cold lysis buffer (10mM Tris HCl, 50 mM sodium bisulfite, 1% 
Triton X-100 (v/v), 10 mM MgCl2, 8.6% sucrose, pH 6.5) and nuclei released by Dounce 
homogenization (glass T type, five strokes). The nuclei were collected by centrifugation (3,000 rpm, 
10 minutes, SS-34 rotor) at 40C and washed three times with the lysis buffer. Histones were extracted 
from the crude nuclear pellets using the procedure of Nakajima et al. (1998). The pellets were 
resuspended in 0.1 ml of ice-cold sterile water using a vortex and concentrated H2SO4 to 0.2 M was 
added. The preparation was incubated at 40C for 1 h, then centrifuged (17,000 rpm, Sorvall SS-34 
rotor) for 10 minutes at 40C. The supernatant containing the extracted histones was mixed with 10 ml 
of acetone, and the precipitate obtained after an overnight incubation at –200C was collected and air-
dried. The acid-soluble histone fraction was dissolved in 50 ul of H2O, and stored at-700C.  
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5. Cell Death ELISA ( enzyme-linked immunosorbent assay) 
     Apoptotic death cells were measured with the use of the cell death ELISA kit (Roche Molecular 
Biochemicals, Indianapolis, IN). The assay is based on quantitative sandwich-enzyme-immunoassay-
principle using mouse monoclonal antibodies directed against DNA and histones, respectively. This  
allows the specific determination of mono- and oligonucleosomes that are released into the 
cytoplasmic fraction of cell lysates during the early stage of apoptosis.  
    Cells (4.0x103) were plated in each well of 96-well plates and treated with either drug in 
5%FBS/DMEM or 5% FBS/DMEM alone (control cells) for 48 or 72 h. Each treatment was performed 
in triplicate. To prepare cell cytoplasmic fractions, the supernatant which contains necrotic cell bodies 
was carefully removed by fast inversion of the plate. The attached cells were resuspended in 200 ul 
lysis buffer, incubated for 30 min at room temperature. The lysate was centrifuged using a microtiter 
plate centrifuge (Sorvall GLC-2B General Laboratory centrifuge) at 200x g for 10 min, and then 20 ul 
of the supernatant (cytoplasmic fraction) was transferred into the streptavidin coated cell culture grade 
microtiter plate (MTP) for analysis. A mixture of anti-histone-biotin and anti-DNA-POD (peroxidase) 
was added and incubated for 2 hours at room temperature. During the incubation periods, the anti-
histone antibody bound to the histone-component of the nucleosomes present in the cell lysate, and 
simultaneously fixed the immunocomplex to the streptavidin-coated MTP via its biotinylation. 
Additionally, the anti-DNA-POD antibody reacted with the DNA-component of the nucleosomes. 
After removal of unbound antibodies by a washing step, the amount of the nucleosomes was quantified 
by the POD retained in the immunocomplex.  POD was determined spectrophotometrically using 
ABTS (2,2-Azino-di-3-ethylbenzthiazolin-sulfonat) as the substrate. The sample absorbances were 
measured at 405 nm in the microtiter plate reader (EL340 BIOKINETICS READER, Bio-Tek 
Instruments, Winooski, Vermont). 
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6. MTS  Assay 
    The MTS assay is based on the reduction of the yellow-colored-tetrazolium compound (MTS)  by 
mitochondrial dehydrogenases of metabolically active cells to a blue formazan product which can be 
measured spectrophotometrically.  It is a measurement of cell viability. 
     MCF-7 cells  were plated at 4.0x103 cells/well in 96-well plates in 225 ul of 5% FBS/DMEM. The 
cells then were grown in a humidified incubator chamber in 7% CO2 at 370 C for 12 h.  Stock solution 
(10mM) of quinidine and other compounds were diluted in the appropriate medium immediately prior 
to use.  Test agents were added at different concentrations into each well of the plate and incubated for 
48 h. Cell proliferation was measured using a MTS assay kit (CellTiter 96 AQueous one solution 
assay, Promega, Madison, WI) according to the manufacturer’s instructions. Briefly, the culture 
medium was removed from each well of the plate; 100ul of DMEM plus 5% FBS were added into all 
wells of the plate; 20ul of CellTiter 96 AQueous One Solution were immediately pipeted into each 
well. The plate was incubated for 2 h at 370 C in a humidified 5% CO2 atmosphere, and the absorbance 
was read at 490nm using the microtiter plate reader (Spectra Max 340PC). This assay is linear for 2.5 
h. 
     Assays run in triplicate were repeated at least two times.  Means  SE were given. The 
concentration of each agent that inhibited cell growth by 50% (IC50) was determined in each case 
using nonlinear regression analysis to fit inhibition data to the appropriate dose-response curve 
(GraphPad Prism version 3.0; GraphPad Software, Inc., San Diego, CA).  
 
 
7. Ki67 Immunohistochemical Assay 
 
     An immunohistochemical assay for Ki67 antigen was performed according to the protocol 
described by Wang et al (1998). MCF-7 cells were plated on 5x5 mm2 95% ethanol-washed glass 
coverslips in 35 mm2 dishes at 2x 105 cells per dish in 5% FBS/DMEM culture medium. After 12 h, 
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cells were treated with different antimalarials  at the IC50 determined in the MTS assay for 48 h. At 
that time point, cells were fixed in acetone:ethanol (50:50)  on ice for 10 min , and then washed with 
Dulbecco’s phosphate-buffered  saline (PBS (140 mM NaCl, 2 mM KCl, 80 mM Na2HPO4.7H2O, 1.5 
mM KH2PO4, pH 7.0))-0.15% bovine serum albumin (BSA),  fraction V (A-9647, Sigma) (PBS-BSA). 
Coverslips were incubated with peroxidase blocking  solution (0.3% hydrogen peroxide in methanol) 
for 10 min. Cells then were rinsed with PBS-BSA, and incubated with 10% horse serum in PBS-BSA 
for 30 min. After incubation, primary antibody for Ki67 (MIB-1, cat # M7240, Dako Corporation, 
Glostrup, Denmark) was diluted in PBS-BSA at 1:77 and added to the coverslips for 60 min. After 
rinsing with PBS-BSA, the coverslips were immediately incubated with second antibody (1:250 in 
PBS-BSA, biotinylated horse anti-mouse IgG, Vector Laboratories, Burlingame, CA) for 30 min. 
Following washing with PBS-BSA, the coverslips were incubated with the avidin-biotin-peroxidase 
reagent (Vector Laboratories) for 30 min. The coverslips were washed in PBS, and the antigen-
antibody complex was visualized using diaminobenzidine (Stable DAB, Research Genetics, 
Huntsville, AL), and then counterstained with Mayer’s hematoxylin (Fisher Scientific, Pittsburgh, PA). 
Finally, coverslips were mounted using Permount (Fisher Scientific, Pittsburgh, PA). Ki67 negative 
cells were visualized by light microscopy (400x objective, Ortholux microscope, Ernst Leitz, Wetzlar, 
Germany). 
       Cells were individually assigned with negative or positive staining, and the Ki67 negative 
percentage of the cell population was determined by counting.  In each coverslip, at least 500 cells 
were counted.  
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8. Oil Red Assay 
    Lipid droplet accumulation, a classic differentiation marker, was measured in breast cancer lines 
using Oil  Red O staining (Graham  et al, 1988).  Oil Red O stock solution (0.5% Oil Red O in 98% 
isopropanol) was prepared.  MCF-7 cells were plated on 5x5 mm 95% ethanol-washed glass coverslips 
in 35 mm2 dishes at 1X 105 cells per dish.  After cells were treated with drug or vehicle for 48 and 72 h 
respectively, cells were fixed in 10% formaldehyde and 0.2% calcium acetate in PBS for 3 minutes and 
then transferred to an Oil Red O staining solution for 10 minutes (Oil Red O stock solution diluted 6:4 
in distilled water, and filtered through No.42 Whatman filter paper (Bancroft et al., 1984)).  The slides 
were washed briefly in distilled water and then counterstained with Mayer's Hematoxylin solution 
(Fischer, Pittsburgh, PA) for 1 min at room temperature. After incubation, slides were washed in 0.4 % 
NH4OH, rinsed in distilled water, and then mounted using 50% glycerol (50:50 glycerol/water (v/v)). 
The lipid accumulation was visualized by light microscopy (400x objective, Ortholux microscope, 
Ernst Leitz, Wetzlar, Germany). 
     Cells were individually assigned  either as negative ORO denoting no lipid or less that 10 lipid 
droplets within a cell or positive ORO cells that had at least 10 lipid droplets per cell. The percentage 
of positive ORO cells was determined;  at least 300 cells were counted . 
 
9. p21(WAF1) ELISA 
     Cells were plated at the density 1x106 cells/100mm2 dish in 5% FBS/DMEM culture medium. After 
12 h, cells were exposed to each antimalarial  at the MTS IC50 for 24 h. The total cell p21(WAF1) 
protein levels were measured using a colorimetric assay (WAF1 ELISA, cat.# QIA18, Oncogen, 
Boston, MA) according to the manufacturer’s instructions. Briefly, the cells were harvested at the 
times indicated by scraping into harvesting buffer (1% SDS and 10mM Tris-HCl, pH 7.4).  Cell lysates 
were boiled for 5 min, and then centrifuged in an Eppendorf microcentrifuge (14,000 rpm, 5 minutes) 
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at 4 0C.  The supernatants were collected. One tablet CompleteTM (protease inhibitor cocktail, cat. # 
1836153, Roche Boehringer Mannheim, Indianapolis, IN) was dissolved in 1.5 ml distilled H2O; 2.5% 
(v/v) of reconstituted protease inhibitor solution was added immediately to the supernatant. The protein 
concentration of the supernatant was determined using a BCA protein assay (Pierce, Rockford, IL) and 
bovine serum albumin as a standard. Fifty ug of cell lysate was transferred into the streptavidin-coated 
cell culture grade microtiter plate (MTP) for analysis. One hundred ul of p21 (WAF1) antibody was 
added to each well, and incubated for 2 h at room temperature. Additionally, 100ul of 1X Streptavidin 
Conjugate (horseradish peroxidase) were pipetted into each well. After removal of unbound antibodies 
by a washing step, the amount of p21(WAF1) was determined spectrophotometrically with substrate 
solution. The samples were measured at 490nm in the microtiter plate reader (Spectra Max 340PC).  
Quantitation is achieved by the construction of a standard curve using known concentrations of WAF1. 
In each experiment, a p21(WAF1) antibody-antigen  standard curve was performed (the samples were 
incubated for 20 min).  By comparing the absorbance obtained from a sample containing as unknown 
amount of WAF1 with that obtained from the standards, the concentration of WAF1 in the sample can 
be determined. 
 
10. Histone Deacetylase (HDAC ) Fluorescent Activity Assay 
     The HDAC Fluorescent Activity Assay (Drug Discovery kit cat # AK-500, BIOMOL Research 
Laboratories, Inc. Plymouth Meeting, PA) was used to screen drugs for the ability to directly inhibit 
HDAC activity. This assay system measures histone deacetylase activity present in a commercial HeLa 
(human cervical cancer cell line) cell nuclear extract, which is rich in HDAC activity. The potent 
HDAC inhibitor, trichostatin A (0.4 uM), was used as  a positive control.  
    The principle of this assay is follows. The HDAC substrate contains  an acetylated lysine side chain. 
After  incubation with the HeLa nuclear extract,  HDAC-mediated deacetylation of the substrate 
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sensitizes the substrate so that, upon addition of a  developer agent, the deacetylated lysine  becomes a 
fluorophore. Briefly, reactions were performed in 50 ul. Fifteen ul of diluted HeLa extract and 10 ul of 
different concentrations of antimalarials were added into appropriate wells of the microtiter plate at 
room temperature; HDAC reactions were initiated by adding diluted substrate (25 ul) to each well and 
mixing thoroughly; the reactions were performed for 10 min, and then the developer (50ul) was added 
into each well of the microtiter plate to stop the HDAC reactions. The plate was incubated at room 
temperature for 10 min, and read in a microtiter-plate reading fluorimeter using an excitation at a 
wavelength in the range 350-380nm and emission in the range 440-460nm (CytoFluor, Muti-well Plate 
Read Series 4000, PerSeptive Biosystems, Farmingham, MA).  
 
 
11. Densitometric Analysis 
    Autoradiograms of the Western immunoblots were scanned using ChemiImager software (Alpha 
Innotech Corporation, San Leandro, CA). The blots were adjusted for brightness and contrast, and the 
mean density for each band was analyzed using ChemiImager analysis program. In this program, a 
rectangle which was called as a object was drawn around the detected spot, the AUTO BACKGRD 
(the program function name) determined the average of the 10 lowest pixel values in each individual 
object and assigned that value  to  the background.  This background value was unique for each object, 
and  was subtracted from all the pixels in the object. Unless specified otherwise, the results shown in 
each case are representative of three independent experiments with similar findings. 
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12. Statistical  Evaluation  
    Data are expressed as the mean ±SER (standard error), with the number of replicates indicated in the 
figure legends. One-way ANOVA (analysis of variance) followed by Bonferroni’s t-tests were used to 
assess statistical significance of difference between control- and drug-treated samples. Differences 
among the means were considered different if p values less than 0.05 were obtained using the 
GraphPad Instat computer program (Intuitive Software for Science, San Diego, CA). 
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1.1.  Introduction 
     Histone deacetylase (HDAC) proteins comprise a family of related proteins that act in conjunction 
with histone acetyltransferase proteins to modulate chromatin structure and transcriptional activity via 
changes in the acetylation status of histones. Histones H3 and H4 are the principal histone targets of 
HDAC enzymatic activity, and these histones undergo acetylation at lysine residues at multiple sites 
within the histone tails extending from the histone octamer of the nucleosome core. The association of 
HDAC proteins with mSin3, N-CoR or SMRT and other transcriptional repressors has led to the 
hypothesis that HDAC proteins function as transcriptional co-repressors (Davie  et al., 1998).  The 
spectrum of genes that show alterations in gene transcription rates in response to decreased HDAC 
activity is quite restricted (Van Lint et al., 1996). Yet, small molecule inhibitors of the enzyme histone 
deacetylase (HDAC) such as trichostatin A (TSA), superoylanilide hydroxamic acid (SAHA), trapoxin, 
and phenylbutyrate cause major alterations in cellular activity including the induction of cellular 
differentiation and apoptosis (Medina et al., 1997; Richon  et al.; 1998; Sambucetti  et al., 1999). 
Trichostatin A, SAHA and trapoxin stimulate histone acetylation by acting as direct inhibitors of 
HDAC enzyme activity (Yoshida  et al., 1999). Trichostatin A, SAHA and trapoxin possess lysine–like 
side-chains and act as chemical analogs of lysine substrates. Molecular models based upon the X-ray 
crystal structure of an HDAC-like protein indicate that trichostatin A and SAHA can bind within the 
active site of the HDAC enzyme and interact with a zinc metal ion within the catalytic pocket that is 
critical for enzymatic activity (Finnin  et al., 1999). Trapoxin is an irreversible HDAC enzyme 
inhibitor (Kajima  et al., 1993).   
     Much remains to be learned about the biochemical events subsequent to HDAC inhibition that lead 
to cell cycle arrest, cellular differentiation, and apoptosis. However, a spectrum of biological responses 
characteristic of HDAC inhibitors has emerged, including cell cycle arrest in G1, elevated p21/WAF1 
expression, hypophosphorylation of retinoblastoma protein (pRb), hyperacetylation of histones, 
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particularly H3 and H4, and apoptosis.  Histone hyperacetylation is directly linked to the activation of 
p21 transcription and is p53-independent (Sambucetti  et al., 1999).  This observation provides an 
important link between HDAC inhibition and cell cycle arrest because p21/WAF1 plays a critical role 
in causing G1 cell cycle arrest via inhibition of the G1 cyclin-dependent kinase family (Xiong  et al., 
1993).  Overexpression of p21/WAF1 has also been associated with apoptosis, but the mechanism of 
p21/WAF1-induction of apoptosis requires further investigation (Sheikh  et al., 1995). 
      Cancer therapy that targets the activity of genes or gene products controlling cell cycle progression, 
differentiation and apoptosis is a promising new strategy. Because HDAC inhibitors regulate the cell 
cycle and cause both cellular differentiation and apoptosis, they comprise an interesting group of 
compounds with potential for development into a new category of clinically significant anti-tumor 
agents. Single, key protein targets for “gene-regulatory chemotherapy” are difficult to identify due to 
the existence of parallel, functionally overlapping signaling cascades.  For this reason, use of cancer 
therapies that target multiple intracellular signaling pathways, such as observed with the HDAC 
inhibitors, is an intriguing approach that addresses the problem of redundancy in growth signaling 
pathways. In this regard, the HDAC inhibitor phenylbutyrate was recently shown to have clinical anti-
tumor activity (Warrel  et al., 1998). 
     Quinidine is a natural product therapeutic agent originally used as an anti-malarial and as an anti-
arrhythmic agent. Previous studies with human breast tumor cell lines demonstrated that quinidine (90 
uM) is an anti-proliferative agent as well. Quinidine arrested cells in early G1 phase, and induced 
apoptosis by 72-96 hr in MCF-7 cells (Wang  et al., 1998), but the biochemical basis for the anti-
proliferative effect of quinidine was not well understood. To clarify the molecular mechanisms of the 
anti-proliferative activity of quinidine, we investigated the effects of quinidine on histone acetylation 
and cell cycle regulatory proteins. In this report, we show that quinidine causes hyperacetylation of 
histone H4, downregulation of HDAC1 protein levels, and cellular differentiation in a panel of human 
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breast tumor cell lines.  We conclude that quinidine is a novel differentiating agent that stimulates 
histone hyperacetylation as a result of HDAC1 protein degradation. 
     
2.2.  Methods 
 
Cell culture 
      Permanent cell lines derived from patients with breast carcinomas were used in these studies.  
MCF-7 cells, passage numbers 40 - 55, MCF-7-ras (Kasid et al., 1985), T47D, MDA-MB-231, and 
MDA-MD-435 cells were maintained in Dulbecco’s Modified Eagle’s medium (DMEM) 
(BioWhittaker, Walkersville, MD) supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
(Hyclone Laboratories, Inc., Logan, Utah), 2mM glutamine, and 40 ug/ml gentamicin. Experiments 
were performed in this medium supplemented with 5% FBS. The cells were maintained at 37 C in a 
humidified atmosphere of 93% air/7% CO2. After six days, cells became about 70-80% confluent and 
were passaged at a 1:5 ratio (MCF-7) or at a 1:10 ratio (all others). Normal human mammary epithelial 
cells (HMEC) were obtained from Clonetics, San Diego, CA were grown according to directions of the 
suppliers. Cells were grown from frozen stocks and used for 1-3 passages.  Quinidine,  TSA, and all 
trans-retinoic acid were purchased from Sigma Chemical Company (St. Louis, MO). The cell permeant 
proteasome inhibitors, MG-132 and lactacystin, were purchased from Calbiochem-Novabiochem (San 
Diego, CA). 
   
Growth inhibition assays 
    Growth inhibition by cell numbers was assayed by plating cells in 35 mm2 dishes (1- 1.5 X 105 ) 
 containing DMEM/ 5% FBS plus quinidine (90 uM).  Viable cells were counted using a 
hemacytometer and trypan blue (0.02%) exclusion was used as an indicator of viability. Cell growth 
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was also monitored in a 96-well plate format using the One Solution Cell Proliferation Assay 
(Promega, Madison, WI), that is based upon metabolic bioreduction of a tetrazolium compound 
(Owen’s reagent) to a colored formazan product that absorbs light at 490 nm. The plating density for 
the 96-well dishes (cells/well) was varied depending upon the relative growth rates of the cell lines as 
follows: HMEC (2000), MCF-7 (1000), MDA-MB-231 (500), T47D (1500), and MCF-7ras (500). The 
One Cell Proliferation Assay Reagent was added to each well and incubated for 2 h at 370C. 
Absorbance (490 nm) was read using a Molecular Devices PC340 (Sunnyvale, CA).  
 
Microscopic Imaging 
     Cells were plated (1 x 105) on sterile coverslips in 35 mm2 dishes, and grown for 96 h in DMEM / 
5% FBS supplemented with either 10 uM all-trans retinoic acid (in 0.01% ethanol) or 90 uM quinidine 
(in H20). Control cells were grown in medium containing a final concentration of  0.01% ethanol. The 
presence of ethanol had no effect upon lipid droplet accumulation compared to cells grown in DMEM / 
5% FBS. Cells were fixed in 3.7% formaldehyde – PBS, rinsed in PBS, then treated briefly with 0.4% 
Triton X-100 in PBS.  After  rinsing three times in PBS, the cells on coverslips were incubated for 30 
min at 370C with a primary antibody to cytokeratin 18 (1:1 dilution, provided by Dr. Guillaume van 
Eys, Maastricht University), rinsed and incubated (30 min/370C) with Texas Red conjugated secondary 
antibody (goat anti-mouse IgG, Sigma).  Alternatively, cells were incubated with fluorescein-
phalloidin (5 ug/0.1ml, Sigma) in the dark for 40 min at room temperature, rinsed and incubated for 5 
min (room temperature) with the fluorescent lipid stain, Nile Red (1:10,000 dilution of a 1mg/ml 
acetone solution, Sigma) (Greenspan et al., 1985 and Toscani et al., 1990). All coverslips were rinsed 
in PBS, and mounted with Fluoromount – G containing 2.5% N-propyl galate. Images were obtained 
using a  Zeiss Axiovert 100 M confocal microscope (63 X objective).  
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Immunoblotting: 
       Cells were harvested from confluent T-75 flasks and subcultured (1x106) in 100mm2 dishes. On   
subcultivation, this confluent population of cells (85% in G1) synchronously proceeded through  the 
cell cycle. To prepare whole cell lysates, the cells were harvested at the times indicated by scraping 
into ice-cold  buffer (50 mM Tris-HCl, 0.25 M NaCl, 0.1% (v/v) Triton X-100, 1mM EDTA, 50 mM 
NaF and 0.1 mM Na3V04, pH 7.4). Protease inhibitors (protease inhibitor cocktail, Roche Molecular 
Biochemicals, Indianapolis, IN) were added immediately. Cell lysates were centrifuged in an 
Eppendorf microcentrifuge (14,000 rpm, 5 min) at 40C, and the supernatants used in immunoblotting 
experiments. 
     Histones were prepared from cells grown at a density of 1 x 107/T-162 flask. To harvest the cells, 
the flasks were placed on ice, and the growth medium removed. Following a quick rinse with ice-cold 
PBS, cells were scraped into 1ml of ice-cold lysis buffer (10mM Tris HCl, 50 mM sodium bisulfite, 
1% Triton X-100 (v/v), 10 mM MgCl2, 8.6% sucrose, pH 6.5) and nuclei released by Dounce 
homogenization. The nuclei were collected by centrifugation (3,000 rpm, 10 min, SS-34 rotor)  and 
washed three times with the lysis buffer. Histones were extracted from the crude nuclear pellets using 
the procedure of Nakajima et al. (1998). The pellets were resuspended in 0.1 ml of ice-cold sterile 
water using a vortex and concentrated H2SO4 to 0.4 N was added. The preparation was incubated at 
40C for 1 h, then centrifuged (17,000 rpm, 10 min, Sorvall SS-34 rotor). The supernatant containing 
the extracted histones was mixed with 10 ml of acetone, and the precipitate obtained after an 
overnight incubation at –200C, was collected and air-dried. The acid-soluble histone fraction was 
dissolved in 50 ul of H2O, and stored at-700C.  
      The protein concentration of the whole cell lysate supernatants or histone preparations was 
determined using the BCA protein assay (Pierce, Rockford, IL) and bovine serum albumin as a 
standard.  Equal amounts of protein were loaded onto SDS - polyacrylamide gels. Molecular weights 
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of the immunoreactive proteins were estimated based upon the relative migration with colored 
molecular weight protein markers (Amersham Life Science Inc., Arlington Heights, IL).   Proteins 
were transferred to polyvinylidene difluoride membranes (PVDF) (Novex, San Diego, CA) and 
blocked at 40C using 5% nonfat milk blocking buffer (1M glycine, 1% albumin (chicken egg), 5% non-
fat dry milk and 5% FBS) overnight. The membranes were incubated with primary antibodies for 3 h at 
room temperature. The antibody sources were as follows: mouse monoclonal anti-p27 (F-8,SC-1641), 
rabbit polyclonal anti-CDK4 (C-22), goat polyclonal anti-HDAC1 (N-19,SC-6299), all from Santa 
Cruz Biotechnology (Santa Cruz, CA), mouse monoclonal anti-pRb (14001A) from PharMingen (San 
Diego, CA), mouse monoclonal anti-cyclin D1 (NCL-cyclin D1, #113105) from Novocastra 
(Burlingame, CA), and mouse monoclonal anti-p16 (Ap-1), p21 (WAF1,Ap-1), p53 (Ap-6) from 
Calbiochem (Cambridge, MA) and anti-acetylated histone H4 antibody (1:500, rabbit polyclonal, 
Upstate Biotechnology, NY). The primary antibodies were diluted at 1:500 in Western washing 
solution (0.1% non-fat dry milk, 0.1% albumin (chicken egg), 1%  FBS,  0.2%(v/v) Tween-20, in PBS, 
pH 7.3). The antigen-antibody complexes were incubated for 1 h at room temperature with horseradish 
peroxidase (HRP)-conjugated secondary antibodies (goat IgG-HRP (SC-2020), rabbit IgG-HRP (SC-
2004) or mouse IgG-HRP (SC-2005) from Santa Cruz Biotechnology) at a final dilution of 1:3000 in 
Western washing solution. After washing three times with Tris-buffered saline (TBS: 10 mM Tris-
HCl, pH 7.5, 0.5M NaCl) and 0.05% (v/v) Tween 20, antibody binding was visualized using enhanced 
chemiluminescence (SuperSignal West Pico, Pierce) and autoradiography.   
 
In vitro HDAC activity assay 
     Quinidine-HCl was added to a chicken erythrocyte cellular extract, which contained HDAC 
activity, at concentrations of 90 uM (Saunders et al., 1999). HDAC assays were performed as 
described in Hendzel et al. (1991). Briefly, the cellular extract was incubated with 500 ug acid-soluble 
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histones isolated from [3H] acetate-labeled chicken erythrocytes for 60 min at 370C. Reactions were 
terminated by addition of acetic acid/HCl to a final concentration of 0.12N/0.72N. Released [3H]-
acetate was extracted using ethyl acetate and quantified by scintillation counting. Samples were 
assayed three times, and the non-enzymatic release of label was subtracted to obtain the reported 
values.  
 
1.3. Results 
 1.3.1. Hyperacetylation of histone H4 
    Antibodies that recognize acetylated forms of histone H4 have been used as a probe for agents that 
cause histone hyperacetylation. (Schmodt  et al., 1999). In Western blot experiments, we compared the 
ability of quinidine to cause hyperacetylation of H4 in MCF-7 cells with that of TSA, an established 
HDAC inhibitor, known to inhibit proliferation in MCF-7 cells (Sun  et al., 1999).  H4 acetylation in 
response to TSA was rapid (within 0.5 h) (Figure 4B) and reached a maximum around 12 h. Some 
level of H4 acetylation persisted in the TSA treated cells for 48 h.  In cells treated with quinidine 
(Figure 4A) detectable H4 acetylation was slightly delayed and could be seen at 2 h but not 1 h of 
treatment. H4 acetylation was  maximal between 12 and 24 h, but then sharply fell to an undetectable 
level at 48 h.    Hyperacetylation of H4 was a transient response to both agents.  Acetylated H4 is 
present in MCF-7 cells but under the conditions of Western blotting and immunochemical staining was 
not detected in control cells (data not shown). 
      HDAC1 is expressed in MCF-7 cells, and this enzyme contributes to the control of histone 
deacetylation rates (Saunders  et al., 1999). Quinidine caused the rapid disappearance of HDAC1 from 
MCF-7 cells. HDAC1 protein levels in quinidine treated cells were reduced after 15-20 minutes 
compared with control cells, and HDAC1 protein was  undetectable between 30 minutes and 6 hours  
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Figure. 4.  Histone Hyperacetylation in MCF-7 Cells.   (A) Histones were extracted from cells 
grown in the presence of 90 uM quinidine for 0.5 , 1, 2, 6, 12 , or 24 h; histones (20 ug/lane) were 
electrophoresed in 15 %polyacrylamide gels containing 1% SDS, and assayed for the presence of 
acetylated  H4 by immunoblotting. (B) Histones were extracted from cells grown in the presence of  
300 nM TSA for 0.5, 6, 12, 24 or 48 h; 20 ug of histone/lane were electrophoresed and analysed for 
acetylated histone H4 by immunoblotting.  (C,D) HDAC1 protein in cell lysates was  prepared from 
control MCF-7 cells at 0.5, 9, 12, 24 or 48 h, control groups were treated with distilled H2O (C) or 
cells treated with 300 nM TSA 0.5, 12, 24 or 48 h, control groups were treated with 0.1% DMSO (D); 
50 ug protein/lane were electrophoresed in 12% polyacrylamide gels containing 1% SDS, and assayed 
for HDAC1 protein by immunoblotting. (E,F) HDAC1 protein in whole cell extracts from cells grown 
in the presence of 90 uM quinidine for (E) 15,20, 30 min or 9,12, 24 or 48 h or (F) 0.5,1,2, or 6 h; 
extracts were electrophoresed (50 ug protein/lane) and assayed for HDAC1 protein by 
immunoblotting. 
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 (Figure 4E and 4F). Partial restoration of HDAC1 protein occurred beginning at 9 h of treatment, but 
even after 48 h, HDAC1 levels in quinidine-treated cells were still less than control cells.  Levels of 
HDAC1 protein in control MCF-7 cells were relatively constant during this time (Figure 4C). TSA-
treated MCF-7 cells also showed reduced levels of HDAC1 protein as early as 30 minutes after drug 
addition, and the reduced HDAC1 protein level was maintained through 48 h (Figure 4D). The data 
indicate that loss of HDAC1 protein might contribute to the H4 acetylation response to both TSA and 
quinidine. However, HDAC1 protein levels were never reduced by TSA below the level of detection as 
was observed with quinidine.  In light of the more extensive H4 acetylation response to TSA than 
quinidine, we conclude that the direct inhibition of HDAC1 catalytic activity by TSA remains an 
important component of the H4 acetylation response in vivo. In addition, the time course of the 
HDAC1 response to quinidine and TSA differ. In response to quinidine, there is initially a more 
marked decrease in HDAC1 protein levels but a more rapid recovery. TSA treatment caused a 
sustained reduction in HDAC1 protein levels through 48 h. 
     To determine if the rapid loss of HDAC protein in the presence of quinidine were mediated through 
the 26S proteasome pathway, MCF-7 cells were treated simultaneously for 30 min with quinidine and 
MG-132 (30 uM), an inhibitor of the 26S proteasome. Cells treated with 90 uM quinidine showed a 
complete loss of HDAC1 protein which was prevented when MG-132 and quinidine were added 
simultaneously (Figure 5A).  Treatment with the solvent, DMSO, or MG-132 in solvent (0.1%) caused 
a modest reduction in the level of HDAC1 protein. These reductions in HDAC1 did not elicit a 
detectable stimulation of H4 acetylation, and we suggest that other HDAC enzymes present in MCF-7 
cells, insensitive to DMSO, could compensate for the lost HDAC1 in the maintenance of deacetylated 
histone H4.  This action of quinidine on HDAC1 protein was not reflected in a general decrease in 
cellular protein content (Wang  et al., 1998), nor were all cell cycle regulatory proteins down-regulated 
in MCF-7 cells in the presence of quinidine  (e.g., p21/WAF1 and p53 protein, Figure 6). Additional  
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Figure 5.  Protection of HDAC1 protein by proteasome inhibitors.  (A)  MCF-7 cells were released 
from confluency and subcultured in normal growth medium supplemented with 30 uM MG-132 in 
0.1% DMSO,  90 uM quinidine plus 0.1%DMSO or 0.1% DMSO alone as indicated. Cells were 
harvested after 30 min, and Western blot analysis of HDAC1 protein was performed as detailed in 
methods.  (B)  MCF-7 cells were cultured as described above, or with lactacystin (3 uM in 0.1% 
DMSO) except were harvested after 24 h, and analyzed for the presence of immunoreactive acetylated 
histone H4. 
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studies are required to define the spectrum of proteins affected by quinidine in a proteasome-sensitive 
manner.   Quinidine (90 or 250 uM) did not inhibit the activity of the isolated chicken erythrocyte 
HDAC1 enzyme in vitro (data not shown) suggesting that quinidine caused histone hyperacetylation 
by eliciting a rapid and transient loss of HDAC1 protein without a direct inhibition of the HDAC 
enzyme. The suppression of HDAC protein levels in MCF-7 cells was accompanied by a decrease in 
HDAC enzyme activity in the cell extracts. Histone acetylation and depressed HDAC1 protein levels 
persisted for approximately 48 h in the presence of quinidine.  When MCF-7 cells were exposed to 
quinidine for 24 h in the presence of either MG-132 or lactacystin, there was no detectable H4 
acetylation (Figure 5B). These results support the idea that quinidine-induced loss of HDAC1 protein 
is involved in the H4 acetylation response via a proteasomal-sensitive pathway.     
 
 1.3.2.  G1 phase cell cycle regulatory profile in MCF-7 cells 
      G1 cell cycle arrest is characteristic of HDAC inhibitors, and reports of alterations in several cell 
cycle proteins in cells exposed to HDAC inhibitors, particularly, the elevation of the p21/WAF1 
protein are numerous (Kim et al., 1999; Saito  et al., 1999; Sowa  et al., 1999). It was of interest to 
determine whether p21/WAF1 and other key cell cycle regulatory proteins such as the retinoblastoma 
protein (pRb) and the G1 phase cyclin-dependent kinase activator, cyclin D1 were targets of quinidine 
action in MCF-7 cells. Western blotting analysis showed that by 12 h, the levels of p21/WAF1 were 
increased in response to quinidine treatment approximately 11-fold, and this elevated level of protein 
expression persisted through 48 h.    A small, less than 2-fold increase in p27 levels was observed in 
cells exposed to quinidine for 24 –48 h, while levels of p16 were not increased (Figure 6).  Quinidine 
treatment decreased cyclinD1 and CDK4 protein levels by 24 h of treatment (Figure 7), indicating that 
the CKI inhibitor, p21/WAF, as well as an important G1 phase target of p21/WAF1, the cyclin D1 / 
CDK4 complex, are early targets of quinidine in MCF- 7 cells.  This profile of activity is consistent  
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Figure 6.  G1 cell cycle proteins in MCF-7 cells.  Cells released from confluency were plated into 
control medium or medium containing 90 uM quinidine. Whole cell lysates were prepared 12, 24 or 48 
h after plating and assayed by immunoblotting for the CKIs , p21/WAF1 (n=3), p27 (n=1) , p16 (n=3) 
and p53 (n =3) after electrophoresis of 50 ug protein/lane through 12% SDS-polyacrylamide gels. Rb 
protein was immunoprecipitated from 500 ug of whole cell lysate protein using an antibody that 
recognizes phosphorylated and non-phosphorylated pRb (Liu, et al., 1999). This entire 
immunoprecipitate was electrophoresed in a 7.5% SDS-polyacrylamide gel and immunoblotted using 
this same antibody.  Results shown are typical of two independent analyses.   
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Figure 7.    Cyclin D – CDK4 in MCF-7 cells.  Confluent MCF-7 cells were subcultured in control 
medium or medium containing 90 uM quinidine. Whole cell lysates were prepared 0.5, 12, 24 and 48 h 
after subculture. Equal protein aliquots (50ug/lane) were electrophoresed in 12 % SDS-polyacrylamide 
gels, and assayed for cyclin D1 and CDK protein levels by immunoblotting. Results shown are 
representative of three independent experiments. 
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with the observed cell cycle arrest of quinidine-treated MCF-7 cells in mid-G1 phase (Wang et al., 
1998).   
     In MCF-7 cell extracts probed using anti-Rb antibodies, two separate but closely migrating bands 
were distinguishable. The upper band contained more highly phosphorylated pRb and the lower band, 
unphosphorylated or hypophosphorylated pRb. Control cells showed a faint pRb signal at 12 h , typical 
of cells in early G1 phase, and increased expression of  both phosphorylated and unphosphorylated 
pRb at 24 and 48 h.   Quinidine treated MCF-7 cells had no detectable hyperphosphorylated pRb at any 
time point examined, and  total levels of Rb protein failed to increase with progression through G1 
phase as seen in the control, proliferating cells (Figure 6).  The decrease in Rb phosphorylation level 
was predictable based on the increase in p21/WAF1 and decreased levels of both cyclin D1 and CDK4 
(Figure 7).  In addition, Nakanishi et al. (Nakanishi  et al., 1999) showed that p21/WAF1 can bind Rb 
protein and block its phosphorylation. However, the actions of quinidine upon p21/WAF1 and 
cyclinD/CDK4 activity do not explain why the levels of total Rb protein were so low.  Reductions in 
the cellular content of phosphorylated Rb protein in MCF-7 cells by quinidine is an important 
additional level of cell cycle control that effectively attenuates progression of cells out of G1 phase, 
and has been reported in other tumor cell lines in response to HDAC inhibition (Levine  et al., 1997). 
In Figure 8 we show data suggesting that the 26S proteasome pathway regulates the total pRb content.  
MCF-7 cells incubated for 24 h in MG-132 or MG-132 plus quinidine had more total pRb than cells 
incubated with quinidine alone.  Thus, quinidine promoted the loss of both HDAC1 and pRb, and 
inhibition of the 26 S proteasome pathway restored the levels of both of these proteins to that seen in 
the untreated cells. We have no direct evidence that quinidine promotes the proteasomal degradation of 
either protein. We hypothesize that quinidine may direct degradation of HDAC1 by the proteasome or, 
alternatively, quinidine might stimulate the proteasomal degradation of other regulatory factor(s) that 
act to maintain HDAC1 and pRb protein levels. 
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Figure 8.   Proteasome inhibitor modulates retinoblastoma protein levels.  Confluent MCF-7 cells 
were subcultured in the presence of 90 uM quinidine, 30 uM MG-132, or quinidine + MG-132 for 24 
h, then harvested, and whole cell extracts (100ug/lane) were analyzed for pRb. A Coomassie blue 
stained  protein is shown as the loading control.    
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MCF-7 cells express wild-type p53 protein.   Normal p53 is a short-lived protein that is maintained at 
low levels, but in response to cell stress or DNA damage, p53 is stabilized and accumulates in the 
nucleus where it functions as a transcription factor inducing p21, G1 cell-cycle arrest and apoptosis 
(Levine  et al., 1997).   Wild-type p53 down-regulates pRb levels in MCF-7 cells (Ameyar  et al., 
1997). Although Saito et al. (Saito  et al., 1999) showed that p53 is not required for pRb 
downregulation by HDAC inhibitors in all cell lines, quinidine-treated MCF-7 cells have elevated p53 
levels (5-7-fold) (Figure 6). Thus, p53 could contribute to the maintenance of the G1 cell cycle arrest 
in MCF-7 by sustaining p21/WAF1 protein levels and suppressing pRb protein levels.  
  
1.3.3.  Growth arrest and cellular differentiation in human breast tumor cell lines 
         In contrast to MCF-7 cells, human breast tumor cell lines T47D, MDA-MB-231 and MDA-MB-
435 express p53 proteins with distinct point mutations (Nieves-Neira  et al., 1999). To test for a 
requirement of p53, this panel of human breast tumor cell lines was exposed to quinidine, and the 
effects of quinidine on cell growth were compared (Figure 9). The data shown are viable cell 
numbers/well,  bioreductive metabolism/well, or both. In all four cell lines growth was suppressed in a 
concentration-dependent fashion between 10 and 90 uM quinidine, and maximal growth inhibition was 
observed at ~90 uM quinidine (data not shown). These data showed that growth suppression by 
quinidine is a p53-independent response.  It is interesting that quinidine was not overtly cytotoxic in 
HMEC, a line of normal human mammary cells (Stampfer  et al., 1993).  
     Evidence that quinidine elicited cellular differentiation in MCF-7 human breast tumor cells in 
conjunction with the inhibition of cell growth was obtained using maximally effective concentrations 
of quinidine or retinoic acid (data not shown). Antibodies directed against cytokeratin 18 (Stingl et al., 
1998) were used to probe the organization of the cytoskeleton (Figure 10). In these studies, all-trans 
retinoic acid (10 uM) was used to compare the differentiation response (Jing  et al., 1996). Control  
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Figure 9.  Growth of human breast cell lines in quinidine.  MCF-7, MDA-MB-231, T47D, MCF-
7ras tumor cells and normal HMEC were replica plated in 96-well plates in control medium (open 
symbols) or medium containing 90 uM quinidine (solid symbols). Cell growth as monitored using the 
MTS assay is shown with solid lines. Results shown are the average of quadruplicates in one 
experiment.  Quinidine had no effect on MTS metabolism in the MCF-7ras cell line (data not shown). 
Viable cell counts/dish of replica plated MCF-7, MDA-MB-231, T47D and MCF-7ras tumor cells and 
normal HMEC cells in 35 mm2 dishes in control medium (open symbols) and medium containing 90 
uM quinidine (solid symbols) is indicated with the dashed lines. The MTS data are the result of  single 
experiments conducted in quadruplicate for  all the cell lines. The cell number  (growth curve data) 
represent the mean and S.E. of three independent experiments for the MCF-7, T47D  and MDA-231 
cell lines performed in duplicate dishes (MCF-7, T47D) or single dishes (MDA-231) for each 
experiment. MCF-7ras data are the mean (± range) of two experiments performed in duplicate dishes.  
HMEC data are from one experiment performed in single dishes.  Data taken from Zhou, et al., 2000 as 
performed by Dr. Zaroui  Melkoumian.   
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MCF-7 cells showed expression of cytoplasmic cytokeratin 18 in a disorganized fashion. Cells that 
were treated for 96 h with retinoic acid showed an increase in the intensity of the cytokeratin 18 
staining and relocalization of cytokeratin 18 throughout the nucleus as well as the cytoplasm.  In 
contrast, cytokeratin 18 staining occurred in a highly organized pattern in MCF-7 cells treated with 
quinidine for 96 h and the cells adopted a shape and nuclear localization more typical of columnar 
epithelium. 
      Lipid droplets are found in the cytoplasm of normal mammary epithelium (Halm  et al., 1990), and 
cytoplasmic lipid droplet accumulation occurs in a variety of differentiating cell systems. Induction of 
differentiation in human breast cancer cell lines by oncostatin M (Douglas  et al., 1998), the HER-
2/neu kinase inhibitor, emodin (Zhang  et al., 1995), overexpression of c-erbB-2 (Giani, etal., 1998) the 
vitamin D analog, 1-alpha-hyroxyvitamin D5 (Mehta  et al., 2000), the HDAC inhibitor, sodium 
butyrate (Bacus  et al., 1990) and retinoic acid (Bacus  et al., 1990)  is accompanied by the 
accumulation of cytoplasmic lipid droplets.  We utilized a fluorescent stain, Nile Red to monitor lipid 
droplet formation in mammary tumor cells in response to quinidine. The cells were counterstained with 
fluorescein-phalloidin that binds actin filaments to assay for changes in the actin cytoskeleton (Figure 
11).  The distribution of actin in four human breast tumor cell lines, MCF-7, T-47D, MDA-MB-231, 
and MDA-MB-435 is seen clearly in the control cells. Three of these lines show strong nuclear 
staining of actin characteristic of transformed cells, while the fourth, MDA-MB-435, shows more 
cytoplasmic actin. In all cases except MDA-MB-435, the presence of quinidine did not significantly 
alter the actin cytoskeleton.  Lipid droplet accumulation was weak or absent in the control cell lines, 
and increased by retinoic acid and quinidine. Lipid droplet accumulation was more marked in all four 
cell lines treated with quinidine than with retinoic acid.  These data demonstrate that induction of a 
more differentiated phenotype is a general response of human mammary tumor cells to quinidine. 
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Figure 10.  Cytokeratin 18 in MCF-7 cells.  Cells were replica plated (2 x 105) on sterile coverslips 
in 35 mm2 dishes in medium containing 0.01% ethanol (control), 10 uM retinoic acid , or  90 uM 
quinidine and grown for 96 hs.  Cytokeratin 18 detection using a Texas red tagged secondary antibody 
is shown using confocal microscopy.  Data shown are typical fields representative of two independent 
experiments. Data taken from Zhou, et al., 2000 as performed by Dr. Zaroui Melkoumian.   
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Figure 11.  Lipid accumulation as an index of cellular differentiation in human breast tumor cell 
lines. MCF-7, T47D, MDA-MB-231 and MDA-MB-435 cells were replica plated  (0.8-3 x 105) on 
sterile coverslips in 35 mm2 dishes in medium containing 0.01% ethanol  (control), 10 uM retinoic acid 
(0.01% ethanol) or 90 uM quinidine (in water). Cells were fixed, permeabilized and then incubated 
sequentially with fluorescein-phalloidin to identify actin filaments and Nile Red to identify lipid 
droplets after 96 h. Images were obtained by confocal microscopy.  The results are typical of three 
experiments conducted in each cell line. Data taken from Zhou, et al., 2000 as performed by Ann 
Lucktong.   
 
 
 
 
 
 
 65 
 
 
 
 
 C o n tr o l R etin o ic  A c id      Q u in id in e
M
C
F
-
7
T
-4
7D
M
D
A
-
23
1
M
D
A
-
43
5
 66 
1.3.4. Hyperacetylation of histone H4 in mammary  tumor cell lines by quinidine   
      To determine whether differentiation and histone acetylation were linked, we investigated the 
histone H4 acetylation status of quinidine treated MCF-7, MCF-7ras, T47D and MDA-MB-231.  All 
four cell lines were incubated for 24 h in the presence or absence of quinidine, and then histones were 
extracted for immunoblotting.  Figure 12 shows that histone H4 was hyperacetylated in all cell lines 
treated with quinidine. Control cells contained no hyperacetylated histone H4.   
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Figure 12.  Histone H4 hyperacetylation in human breast tumor cell lines.  MCF-7, MDA-MB-
231, T47D and MCF-7ras tumor cells were replica plated (1 x 107/T-162 flask) in control medium (C) 
or medium containing 90 uM quinidine (Q) . Histones were extracted from the cells after 24 h, and 
20ug/lane of histone proteins were electrophoresed in 15% SDS-polyacrylamide gels. Immunoblotting 
was performed to detect acetylated histone H4.   
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Table 1. Summary of effects of quinidine on cell cycle proteins in MCF-7 cells.  Protein
signals were analyzed from autoradiographic signals on X-ray film using Molecular Dynamic
Research Densitometer. These signals were estimated as fold changes due to the limitation of the
x-ray film sensitivity. Quantitation of signal density for each  the cell cycle regulatory protein
expression is shown as fold induction of the protein by quinidine treatment over the control group.
“+” indicates increase in  protein level; “-” indicates decrease in protein level. Data are presented
as the mean±SER of values from typical experiment. 
  70 
 
 
 
Table 1. Summary of Effects  of Quinidine on Cell cycle Regulatory Proteins in 
MCF-7 Cells 
 
 
Proteins 
 
12h 24h 48h 
P21(n=4) 11.2±1.1 9.2±1.8 9.3±1.2 
P53(n=3) 6±0.2 5±0.3 7.4±0.5 
P27(n=1) 1.2 1.8 3.2 
Cyclin D1(n=3) -5.6±0.3 -2±0.4 -4.0±0.7 
CDK4(n=3) -1.1±0.5 -3.5±0.4 -4.0±0.2 
pRb(n=2) 3.0±0.8 -17±0.5 -15±0.4 
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1.4. Discussion 
           
     
Quinidine-induced histone H4 hyperacetylation in MCF-7 human breast carcinoma cells can be 
attributed to the rapid elimination of HDAC1 protein, a response that was blocked by MG-132 and 
lactacystin, two inhibitors of proteasome-mediated proteolysis. HDAC1 protein was undetectable 
within 30 min after the addition of quinidine to the medium of MCF-7 cells, and hyperacetylated 
histone H4 appeared between 1 and 2 h. Levels of HDAC1 protein were completely suppressed 
between 0.5 and 6 h, and during this time H4 acetylation levels increased.  H4 acetylation was 
maintained at 12 and 24 h, despite the partial restoration of HDAC1 protein at these same time points. 
These data indicate that quinidine induced reductions in HDAC1 protein levels are unlikely to fully 
explain the regulation of H4 acetylation state in MCF-7 cells by quinidine. Additional HDAC enzymes 
or effects upon histone acetylation rates could possibly play a role as well.   
      An earlier study showed that over this initial 48 h period, 80 % of the MCF-7 cell population had 
shifted into G0, a quiescent state marked by the absence of Ki67 antigen immunoreactivity (Wang et 
al., 1998). Cellular differentiation manifested as the accumulation of lipid droplets and a reorganization 
of the cytokeratin 18 cytoskeleton was evident after this initial 48 h period.  Quinidine exhibited all the 
responses typical of known HDAC inhibitory drugs, with the exception that quinidine had no direct 
inhibitory effect upon HDAC1 enzymatic activity. We conclude from the current studies that quinidine 
is a novel differentiating agent that causes histone hyperacetylation, in part, by physical elimination of 
HDAC1 protein rather than the inhibition of HDAC enzymatic activity.   
      Histone H4 hyperacetylation and induction of cellular differentiation by quinidine were seen in a 
panel of human breast tumor cell lines that were selected for study on the basis of their diversity of 
genetic backgrounds. The differentiation response to quinidine was independent of the estrogen 
receptor (ER) status. Cell lines representative of ER-positive and ER-negative human breast carcinoma 
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cells were induced to differentiate in the presence of quinidine. The ER status of the estrogen receptor 
positive cell lines is MCF-7 (ER-alpha, ER-beta), T47D (ER-alpha and ER-beta), and MDA-MB-231 
(ER-beta). MDA-MB-435 cells expressed very low levels of ER-beta  (Fuqua  et al., 1999;  Vladusic et 
al., 2000).  MCF-7 and T47D cells display an epithelial morphology and show similarities with 
mammary ductal and luminal epithelial cells, respectively (Jin  et al., 1996; Soule etal., 1973).  MDA-
MB-231 exhibit an elongated cellular morphology which is also typical of MDA-MB-435 cells.  Our 
results demonstrate that quinidine is a differentiation agent in both types of mammary tumor cells.   
HDAC inhibitors reverse the transformed phenotype of NIH3T3ras cells, and this property has 
been used successfully as a screening assay for the identification of new HDAC inhibitors (Jones  et 
al.; 1997; Sweeney  et al., 1998).  Quinidine elicited a more differentiated phenotype in MCF-7ras 
cells, an MCF-7 cell derivative produced by stable transformation with v-Ha-ras, thus demonstrating 
that quinidine, like other HDAC inhibitors, can reverse an H-ras induced phenotype. 
         
Quinidine induced differentiation independently of wild-type p53.  The ability of quinidine to 
cause differentiation of p53 mutant cell lines is consistent for a role of histone hyperacetylation in the 
response.  HDAC inhibitors typically induce a p53-independent activation of p21/WAF1 gene 
expression (Sambucetti et al., 1999; Saito  et al., 1999). Growing MCF-7 and T47D cells express 
p21/WAF1 protein in moderate to low levels (Sheikh  et al., 1994), and quinidine raised p21/WAF1 
protein levels in MCF-7 cells approximately 11-fold within 12 h.  Although p21/WAF1 was reported 
to be low to undetectable in MDA-MB-231, p21/WAF1 was detected in Western analyses of both 
MDA-MB-231 and T47D cells in a p53-independent fashion in response to serum deprivation, 
adriamycin, etoposide (Sheikh  et al., 1994; Futamura  et al., 1995), and  quinidine (data not shown). 
These data support the idea that the p21/WAF1 gene is present, but inactive in growing MDA-MB-231 
cells. Since histone  hyperacetylation of the p21/WAF1 gene occurs in response to HDAC inhibitors, it 
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might be involved in the pathway of p53-independent activation of p21/WAF1 gene expression 
(Sambucetti etal., 1999).  
The processes of cellular differentiation and cell cycle progression are interdependent. G1 
arrest is a necessary but insufficient condition for differentiation in numerous cell types including 
leukemic cells, keratinocytes, colonic epithelium, and muscle cells. In all of these cells, induction of 
p21/WAF1 protein and G1 cell cycle arrest occurred prior to differentiation  (Itazaki  et al., 1990; 
Chang et al., 1999; DiCunto  et al., 1998;  Evers  et al., 1996; Freemerman  et al. 1997;  Missero  et al., 
1996; Matsumura  et al., 1997), and was generally independent of p53. We hypothesize that the 
differentiated state can be viewed as a cellular response to G1 arrest, requiring a change in gene 
expression profile and suppression of cell death pathways. The response of MCF-7 breast tumor cells 
to quinidine is consistent with this model. 
     To begin to understand how quinidine might elicit G1 arrest of MCF-7 cells, we have focused on 
the action of quinidine as a potassium channel blocking agent. Quinidine enters cells and inhibits 
cardiac potassium channels by binding to the intracellular face of the ion pore (Yeola et al., 1996).  
Although the location of the quinidine binding site on the ATP-sensitive potassium channel is 
unknown, quinidine is freely permeable across membranes and inhibits the ATP-sensitive potassium 
channels whether it is applied to the external or internal surface of a lipid membrane bilayer (Watson  
et al., 1996).  
          In the presence of quinidine, MCF-7 cells accumulate at a position 12 h into G1 phase (Wang  et 
al., 1998).  This position, defined by cell cycle arrest and release experiments, precedes the lovastatin 
arrest point by 5-6 h, and is clearly distinct from the restriction point described by Pardee (Pardee et 
al., 1974) near the G1/S transition. The present work showed that quinidine treatment caused elevated 
levels of p53 and p21/WAF1 protein by 12 h (Figure 6), the point within G1 where MCF-7 cells arrest 
in response to quinidine (Wang  et al., 1998).  When p53 and p21/WAF1 proteins were assayed before 
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12 h, p53 was undetectable, and p21 was first detected after 8 h of quinidine treatment (data not 
shown), suggesting a p53-independent induction of p21/WAF1 occurred prior to arrest in G1. Cdk4 
and cyclin D1 protein levels were also reduced, as was cdk4 activity as demonstrated by the abundance 
of hypophosphorylated Rb protein. Based upon our observations in MCF-7 cells, we conclude that 
p21/WAF1 protein levels become elevated prior to the G1 arrest in response to quinidine, and could 
initiate the G1 arrest. Hypophosphorylated Rb  protein is prominent in quinidine-treated MCF-7 cells 
and this could act to sustain the G1 state by preventing the transition into S phase.  The G1 arrest 
induced by quinidine in MCF-7 cells was correlated with the blockade of ATP-sensitive potassium 
channels in MCF-7 cells (Wang  et al. 1998; Woodfork  et al., 1995;  klimatcheva  et al., 1999). Direct 
evidence for the involvement of potassium ions in the G1 arrest was provided using valinomycin a 
potassium-selective ionophore to stimulate a G1 - S phase transition in the presence of quinidine 
(Wang  et al., 1998). 
     In summary, quinidine, a drug that is used therapeutically in the treatment of malarial infections and 
cardiac arrhythmia, was shown to be useful as an inducer of cellular differentiation in human breast 
tumor epithelial cells. Quinidine caused histone H4 hyperacetylation and cellular differentiation in 
human breast tumor cells following the rapid loss of HDAC1 involving a proteasome-dependent 
pathway.  Additional experiments are needed to determine how the action of quinidine upon ATP-
sensitive potassium channels initiates the molecular events underlying the differentiation response. 
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2. Effects of  Antimalarials on  Cell  Growth, Differentiation and Apoptosis in Human Breast  
Cancer Cells 
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2.1. Introduction 
  
       Quinidine, a quinoline antimalarial, is a growth inhibitor of breast cancer cells, which may be 
useful for adjunct therapy of human breast cancer. We have shown that inhibition of MCF-7 cell 
growth in response to quinidine involves cell cycle arrest in G1/G0 phase followed by apoptotic cell 
death (Wang et al., 1998).  Quinidine induces a variety of changes within the nucleus, including 
elevated p21(WAF1) protein and hyperacetylation of histone H4 (Zhou et al., 2000). Overexpression 
of the cyclin-dependent kinase inhibitor p21(WAF1) by quinidine might be through a process that 
involves activation of tumor suppressor gene p53. We also reported that antiproliferative actions of 
quinidine might involve activation of proteasome pathway, which, in part, degrades HDAC1 protein 
without directly inhibiting HDAC activity (Zhou et al., 2000). Quinidine is a novel HDAC inhibitor, 
and bears potential as new antitumor drug because of its ability to induce p21(WAF1) protein and to 
trigger differentiation and apoptosis. Quinidine also caused a decrease in cyclin D1 protein expression 
(Zhou et al., 2000). This is relevant to the potential use of quinidine in cancer therapy, because cyclin 
D1 has been strongly associated with proliferation and carcinogenesis in the mammary gland (Buckley  
et al, 1993).  
        We hypothesized that effects of quinidine on HDAC and apoptotic response were generalizable to   
quinoline antimalarials. To test this hypothesis, we screened quinoline antimalarials, including 
amodiaquin, chloroquine, halofantrine, mefloquine, primaquine, quinine, quinoline and quinolinic acid, 
for the ability to inhibit tumor cell growth. In this study, the main work is to determine if quinoline 
antimalarials exert their growth regulatory effects on MCF-7 cells via common mechanisms which 
involve cell cycle arrest, differentiation, apoptosis, and induction of hyperacetylated histone H4 
without directly inhibiting HDAC activity. The selection of these molecular targets is based on the fact 
that  they are the major contributors, possibly causative, to the mechanisms of breast cancer cell death. 
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The long-term goal of these studies is to obtain structure-activity information that will enable us to 
predict unique chemical structures with greater potency.   
      The molecular mechanisms by which quinidine induces apoptosis have been postulated including 
inhibition of anti-apoptotic Bcl-2 protein, and increase in cytochrome c release, which are a central 
coordinating events in apoptosis (Zhou and Strobl, 2000). However, the mechanism of quinidine-
induced apoptosis still remains to be clarified. 
      One cell cycle-related gene implicated in quinidine action is pRb.  The histone deacetylase HDAC1 
physically interacts and cooperates with pRb, and there is evidence that this complex is a key element 
in the control of proliferation and differentiation (Magnaghi-Jaulin et al., 1998). Quinidine treatment 
leads to pRb hypophosphorylation, and this is likely to be involved in the mechanisms underpinning 
quinidine inhibition of cell proliferation. We probed whether pRb status modulates quinidine-induced 
apoptosis. MDA-MB-468 cells, pRb deficient breast carcinoma cells were used for this work. In the 
current study, we also determined whether caspase-3 might influence the apoptotic responses of MCF-
7 cells to quinidine treatment.   
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2.2. Results 
2.2.1. Effects of TSA on cell growth and HDAC activity 
     Trichostatin A (TSA), a specific and potent inhibitor of HDAC, inhibits cell growth, blocks cell 
cycle progression  in  G1 phase, induces  differentiation,  and causes apoptosis in many breast cancer 
cell  lines (Vigushin  et al,  2001, Kim  et al;  2000 and Furumai  et al, 2001).   TSA is the most well 
studied HDAC inhibitor,  and  its effects on cell cycle, HDAC activity,  and  p21(WAF1) reporter gene  
expression  have been published (Kosugi et al., 1999 and  Furumai et al., 2001). Yet, interpretation of 
these data is confusing because the concentration of TSA in published reports varies from low 
nanomolar to micromolar concentrations. We have reported that 300 nM TSA causes hyperacetylation 
of histone H4  by 12 h in MCF-7 cells (Zhou et al., 2000).  The TSA concentration-response in MCF-7 
cells for several end -points are now reported in the following study; we compared the concentration-
response  effects  of TSA on cell viability and HDAC activity in MCF-7 cells.  
      The MTS assay at 48 h of TSA exposure shows that TSA induced a concentration-dependent 
decrease in MCF-7 cell growth (Figure 13A). The MTS IC50 value of TSA is 35nM in MCF-7 cells. 
The IC50 value of TSA for HeLa HDAC activity  is 8.4 nM (Figure 13B).  
 
2.2.2. Effects of TSA on Ki67 antigen and p21(WAF1) protein in MCF-7 cells 
      Ki67 is a nuclear protein that is expressed in all phases of the cell cycle (Van  et al., 1989). The 
absence of Ki67 protein from cells is a marker that cells have exited the cell cycle (Van  et al., 1989). 
The percentage of Ki67 negative cells in the TSA-treated cell population is an indication that TSA 
causes cell cycle exit.  About a 5-fold increase in Ki67 negative cells was observed after 48 h TSA 
treatment  compared to control group (Figure 14A).  
     Transcription of p21(WAF1) and  p21(WAF1) protein levels  have been shown to be increased by 
TSA (Yoshida et al., 1999 and Kim et al., 2000). p21(WAF1) has also been shown to play an  
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Figure 13.  Effects of TSA on cell growth and HDAC activity in human  carcinoma cells. (A)  
TSA inhibited MCF-7 cells growth. MCF-7 cells ( 4000 cells/well) were plated in 96-well plates; 12 h 
after plating, cultures were treated with indicated concentrations of TSA. Total cells were determined 
after 48 h of treatment using the MTS assay. Cell growth  was presented as percentage of vehicle 
control (0.01% DMSO). Data are meanSER of two independent assays performed in quadruplicate. 
(B) Effect of TSA on HDAC activity of HeLa cell nuclear extracts. The assay is described in Materials 
and Methods.  The enzyme activity was expressed as a percentage of the control. Data represent mean 
 SER of three independent experiments. 
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Figure 14.  Effects of TSA on Ki67 negative cell population  and p21(WAF1) in MCF-7 cells. (A)  
MCF-7 cells were plated (2x105) in 35-mm2 dishes on sterile glass coverslips and grown in DMEM 
plus 5%FBS. Cells were treated with solvent (0.01% DMSO), or TSA 35nM for 48 h. Cells were 
stained for Ki67 immunoreactivity. The bar (the mean ± SER) represents the percentage of Ki67 
negative cells in each treatment group. Data are from two independent experiments in which 500 cells 
per experiment condition were counted. (B) MCF-7 cells were plated at a density of 1x106 cells/100 
mm2 dish. Cells were cultured in DMEM with 5% FBS and at 80% confluency were treated with 
solvent (0.01% DMSO), or TSA 35nM  for 24 h. Cell lysate was obtained at the indicated time points. 
Proteins (50ug) from the cell lysates  were assayed for p21(WAF1) protein using an  ELISA kit. Data 
are the mean ± SER of two independent experiments.   
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important role in G1 to G0 cell cycle transition and differentiation (Xiong et al., 1993; Doglioni et al., 
1996). To determine whether p21(WAF1)  is regulated  in MCF-7 cells by TSA, the levels of 
p21(WAF1) in control and TSA-treated MCF-7 cells were examined using a p21(WAF1) ELISA.  
p21(WAF1) protein levels increased 5-fold in MCF-7 cells exposed 35 nM TSA for 24 h (Figure 14B).  
 
2.2.3. Induction of differentiation by TSA in MCF-7 cells 
      The effect of TSA on cell differentiation was determined by ORO staining. As seen in Figure 15,   
lipid droplets accumulated in the cytoplasm around the nucleus in MCF-7 cells exposed to 35 nM TSA 
for 48 h. Lipid droplets were still present up to 72 h after TSA addition (data not shown).  Figure 16 
shows that 20, 30, and 40 nM of TSA treatment significantly increased cytosolic accumulation of lipid 
droplets in MCF-7 cells compared to control cells (p<0.05). Collectively, these results indicate that 
induction of p21(WAF1) protein, G0 transition ( loss of Ki67 antigen expression),  and differentiation 
(lipid droplet accumulation)  occurred in MCF-7 cells treated with a TSA concentration that reduces 
MTS activity by 50%.   
 
2.2.4. Effect of TSA  on  apoptosis in MCF-7 cells 
      Apoptotic cell death was quantitated in MCF-7 cells following treatment with TSA using a cell 
death ELISA that measures soluble DNA-histone complexes generated during cell apoptosis. MCF-7 
cells treated with increasing concentrations of TSA for 72 h exhibited a concentration-dependent 
increase in the number of soluble DNA-histone complexes, but the MTS IC50 for TSA (35nM) did not 
increase DNA-histone complex formation (Figure17). We conclude that the MTS IC50 TSA was 
sufficient to cause differentiation but not  apoptosis,  and the induction of  
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Figure 15.  Induction of differentiation  by  TSA treatment in MCF-7 cells for 
48 h.  (A) and (B) Cells (1x105 cells per 35mm2 culture dish) were grown on 
coverslips treated with solvent only (0.01% DMSO),  or TSA 35 nM for 48 h; cells
were stained with Oil Red O and counterstained with hematoxylin as described in
“Materials and Methods”. Cells were visualized using light microscopy (x400). (C)
Data are presented as percentage of ORO positive cells in solvent and treatment
groups. The data are from three experiment in which 300 cells per treatment were
counted. *, p<0.05  for TSA treatment versus control group using  paired t-tests.  
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Figure 16. Induction of differentiation by TSA  in MCF-7 cells. Cells (2x105 cells per 
35mm2 culture dish) were cultured with  0.01%DMSO, or increasing concentrations of TSA 
for 39 h, at which time the lipid droplets were determined as an indicator of terminal
differentiation using Oil Red O staining. The data are presented as the percentage of Oil Red
O positive cells for each treatment. Data are mean SER of three independent assays. *, 
p<0.05  for TSA treatment versus control group using ANOVA followed by  Bonferroni’s t-
tests.  
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Figure 17. Nucleosome release in the cytoplasm of MCF-7 cells treated with TSA. MCF-7 cells 
(4000 cells/well in a 96-well plate) were incubated for 72 h with increasing concentrations of TSA. 
Cells were lysed, and mono- and oligonucleosome levels were determined by cell death detection 
ELISA.  The release of nucleosomes of each sample was monitored by the absorbance at 405 nm. Data 
are mean  SER of three independent experiments, each performed in triplicate. **, p<0.01 for TSA 
treatment versus control group  using ANOVA followed by Bonferroni’s t-tests.  
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differentiation was effected at a lower threshold concentration than that required for induction of 
apoptosis in the MCF-7 cell line.  
 
 2.2.5. Antimalarials  inhibit  MTS metabolism in MCF-7 cells  
       Quinidine is known to inhibit cell proliferation in MCF-7 cells (Wang et al., 1998; Zhou  et al., 
2000). To compare the effects of other antimalarials on cell growth of MCF-7 cells, we determined the 
cell growth arrest upon treatment with antimalarial drugs using the MTS assay. The IC50 after 48 h 
was calculated for each drug (Figure 18A). Mefloquine and primaquine were the most potent cell 
growth arrest agents, and  quinidine was least potent agent in this assay. As shown in Figure 18B, there 
was an initial loss of about  60% of the cell population by chloroquine treatment for  60 h. Quinoline, 
quinidine and quinine  caused  growth arrest (no change in cell number)  within 60 h. 
      MTS reduction activity could be affected within 4 h (Berridge, et al., 1993).  To study whether  
antimalarials effect early changes in mitochondrial dehydrogenase in MCF-7 cells, the MTS IC50 of 
each antimalarial was added to MCF-7 cells for 2 or 6 h. Figure 19 indicates that only primaquine 
treatment significantly inhibited the activity of mitochondial dehydrogenase at times up to 6 h  
compared to control group (p<0.05). No significant changes in mitochondial dehydrogenase were 
detected in MCF-7 cells treated with the other tested compounds for 2 or 6 h. MTS IC50 of 
antimalarials did not affect cell viability within 2 h (Figure 20).  
 
2.2.6. Hyperacetylation of histone H4 by antimalarials in MCF-7 cells 
    To analyze the effects of quinoline ring-containing antimalarial drugs on histone acetylation, 
Western blot assays were performed to detect acetylation of  histone H4 in MCF-7 cells exposed to 
MTS IC50 of each antimalarial compound.  Quinidine, quinine, and chloroquine  possess a  quinoline 
base ring structure and a  tertiary amine  side chain. Since quinidine causes hyperacetylation of histone  
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Figure 18. Antimalarials inhibit MCF-7 cell growth. (A) Antimalarials Inhibit MTS 
Metabolism  in MCF-7 cells. MCF-7 cells were grown in the presence of  increasing 
concentrations of each compound  for 48 h, and cell viability was estimated using the MTS
assay. The  IC50 value for each agent was determined using nonlinear regression analysis 
to fit  the inhibition data. The results are the average of  at least two independent
experiments carried out in quadruplicate, and are presented as the means ± SER of the
percentage of untreated, control cells.  The IC50 value for each compound is shown in the 
table.  Typical or a  complete concentration response curve for each compound is shown in
Appendix 1.  (B)  Effects of antimalarials on cell growth. MCF-7 cells (5x105) growing in 
60mm2  dishes in 5% FBS/DMEM were treated with concentrations of antimalarials 
corresponding to 50% inhibition of MTS activity as measured at 48 h. After 60 h
incubation with antimalarials or solvent alone,  viable cells that excluded trypan blue  were
counted using hemacytometer. Data are the mean of n=3SER independent experiments. 
Abbreviations: AQ (amodiaquin), CL (chloroquine), ETOH (ethanol), HF (Halofantrine),
MQ (Mefloquine), QA (quinolinic acid), QL (quinoline), QD (quinidine),  PQ
(primaquine), and QN (quinine). 
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Compound         MQ            PQ              AQ              HF               QA               CL              QN                QL             QD
IC50 (log uM)      0.48           0.52               0.84           1.03             1.46             1.483           1.6              1.79             2.04
   (SER)               (0.162)      (0.13)            (0.073)       (0.089)        (0.125)         (0.157)        (0.08)           (0.3)            (0.3)
N                      3                4                   2                  2                2                   5                  3                 2                  4
uM                  3.0             3.4                7.0               11.0           28.0              33.0             40.0            62.0             110.0
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Figure 19. Effects of  antimalarials and TSA on MTS metabolism  in MCF-7 cells. 
MCF-7 cells were grown in the presence of  MTS IC50 of each compound  for 2 h (A) or 6
h (B), and cell mitochondria metabolism was estimated using the MTS assay. The results 
are the average of  one experiment carried out in quadruplicate, and are presented as the
means ± SD.  The microtiter plates were incubated with MTS for 1 h at 37 0C, and the 
absorbance was read at 490 nm using the microtiter plate reader. *, p<0.05  for compound 
treatment versus control group using ANOVA followed by Bonferroni’s t-tests.  
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Figure 20. Effects of antimalarials and TSA on cell viability. MCF-7 cells (5x105) were 
growing in 60mm2  dishes in 5% FBS/DMEM, and  treated with concentrations of
antimalarials corresponding to 50% inhibition of MTS activity as measured at 48 h. After 2 h
incubation with each compound or distilled H2O alone (control),  viable cells that excluded 
trypan blue  were counted using hemacytometer. Data are the mean of n=3SER 
independent experiments. 
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Figure 21.  Hyperacetylation of histone H4 by antimalarials in MCF-7 Cells. 
Histones were extracted from cells grown  either in the presence of compound  or solvent
control (distilled H2O or 0.1% ethanol) for 12  or 24 h. Histone proteins were
electrophoresed in 10 % SDS-polyacrylamide gels, and assayed for the presence of
acetylated  H4 by immunoblotting.  (A) Cells were treated with either MTS IC50 of
antimalarials  or 0.1% ethanol (control) for 24 h. Recombinant histone H4 proteins (20ug)
were used as the negative control for acetylated histone H4 antibody.  (B) Cells  were
treated with either amodiaquin 10 uM  or distilled H2O (control) for 24 h. (C) Cells were 
treated with quinidine, primaquine, or halofantrine for 24 h. (D) Cell were treated with  0-, 
10-, 50-, and 90 uM of quinine for 12 h.  (E) Summary of effects of antimalarials on
acetylation of histone H4 protein in MCF-7 cells. “+”, agent induced acetylated histone 
H4; “-”, agent did not cause induction of acetylated histone  H4. 
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H4, we hypothesized that these antimalarials might be the same or related. Quinoline antimalarial 
compounds lacking a tertiary amine side chain (quinoline or quinolinic acid) were used as negative 
control to test this hypothesis. 
     As shown in Figure 21, 4-alkylamino substituted qunolines (chloroquine and amodiaquin), and an 
8-amino substituted quinoline (primaquine) induced hyperacetylation of histone H4 in MCF-7 cells 
treated with their MTS IC50. Hyperacetylation of histone H4 was also observed in cells treated with 
halofantrine, quinidine and its stereoisomer quinine. Those are 4-amino substituted quinoline ring 
compounds containing a quinuclidine ring, and have structural parallels with amodiaquin and 
chloroquine. Mefloquine, quinoline and quinolinic acid that lack alkylamino-substituted quinoline 
rings did not increase acetylated histone H4 level. The data indicates that alkylamino-substituted 
quinoline ring might be important for acetylation of histone H4. 
 
2.2.7. Effect of quinoline antimalarial drugs on  HDAC activity in vitro  
    The effect of quinoline antimalarials on HDAC activity in vitro was assessed using a fluorescent 
enzyme assay. Histone deacetylases came from HeLa cells. As shown in Figure 22, none of 
antimalarials we tested inhibited HDAC activity compared to control (p>0.05). TSA was used as a 
positive control in these assays. IC50 TSA, 8.5nM, significantly inhibited in vitro HDAC activity  
compared to control (p<0.05). 
 
2.2.8. Effects of antimalarials on Ki67  antigen in MCF-7 cells 
    We  analyzed the effects of antimalarials on the cell cycle of the MCF-7 cells by performing Ki67 
immunohistochemical staining.  MCF-7 cells were treated with each antimalarial (MTS  IC50) for 48 
h. We observed that the percentage of Ki67 negative immunoreactive cells. Chloroquine, quinidine,  
quinine, -treated cell populations  showed  highly significant increases (p<0.01) (Figure 23). Moreover, 
 95 
an increase in the percentage of Ki67 negative cells also was observed in amodiaquin (p<0.05). This 
result indicates that amodiaquin, chloroquine, quinidine as well as quinine caused cells to enter G0 
phase. No significant changes in the percentage of Ki67 negative cells were detected after treatment of 
MCF-7 cells with the other listed antimalarials (p>0.05). We conclude that only a subset of quinoline 
antimalarials stimulates exit of MCF-7 cells from the cell cycle. 
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Figure 22.  Effect of antimalarials on HDAC activity in HeLa cell nuclear extracts. Assay was 
performed using MTS IC50 of each compound as described in “Materials and Methods”. In panel A 
and B, control groups were treated with distilled H2O; in panel C, the control group was treated with 
0.1% ethanol.  Data represent the average of three different experiments, each performed in triplicate; 
bars, SER. *, p<0.05  for compound treatment versus control group using ANOVA followed by 
Bonferroni’s t-tests.  
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Figure 23.  Ki67 expression in MCF-7 cells after treatment with antimalarials.  MCF-7 cells were 
plated (2x105) in 35-mm2 dishes on sterile glass coverslips and grown in  5% FBS/DMEM. Cells were 
treated with vehicles (distilled H20, or  0.1% ethanol), or the MTS IC50 of each compound for 48 h. 
Halofantrine and mefloquine were dissolved in  95% ethanol; other listed antimalarials were dissolved 
in distilled H2O.  Cells were stained for Ki67 immunoreactivity as  previously described  by Wang et 
al. 1998. The bars represent the percentage of Ki67 negative cells in  each treatment group. Data are 
the mean of n=3SER independent experiments in which 300 cells per experiment condition were 
counted. *,p<0.05; **,p<0.01 for compound versus control group using ANOVA followed 
Bonferroni’s t-tests.  
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2.2.9. Effects of antimalarials on  p21(WAF1) protein in MCF-7 cells 
      Because p21(WAF1) is rarely mutated in human cancer cells, induction of p21(WAF1)  by drugs 
might be an important molecular target for anticancer therapy. We examined the effect of antimalarials 
on changes in p21(WAF1) protein. As shown in Figure 24, a p21(WAF1) ELISA was used to test if 
p21(WAF1) protein expression increased in MCF-7 cells exposed to quinoline antimalarial drugs for  
24 h. In our experiments, each drug was used at the MTS IC50.   Protein p21(WAF1) was increased in  
chloroquine and quinidine treated cells, but not either in quinoline or  other tested antimalarials. 
Trichostatin A (TSA) was used as a positive control for these experiments. Transcription of 
p21(WAF1) and  p21(WAF1) protein levels have been shown to be increased by TSA (Kim  et al., 
2000). Western blot analysis was performed on MCF-7 cell extracts to confirm the changes in 
p21(WAF1) protein in response to the antimalarials ( comparison shown in Figure 25A). The results 
from Western blot analysis are consistent with the results by ELISA (Figure 25C). Amodiaquin, 
halofantrine, mefloquine, primaquine, quinolinic acid and quinoline did not increase p21(WAF1) 
protein levels (Western blot data not shown).  Chloroquine caused a 10-15 fold elevation in 
p21(WAF1) levels in MCF-7 cells at 24 h. The p21(WAF1) response to chloroquine exceeded that of 
the potent histone deacetylase inhibitor, TSA. Quinidine elevated p21(WAF1) levels 4-5 fold, 
approximately the same  as TSA, but neither quinine nor amodiaquin raised p21(WAF1) protein.  
 
2.2.10. Effect of antimalarials on lipid droplet accumulation in MCF-7 cells 
    The effects of quinidine and other listed quinoline compounds on lipid accumulation were compared 
using ORO staining.  The percentage of MCF-7 cells with  lipid droplets  in cells exposed to MTS 
IC50  of compounds for 48 h  is shown in Figure 26  Quinidine (110uM) caused positive ORO staining 
in 65% of MCF-7 cells by 48 h.  Fifty percent ORO positive cells was achieved by  and quinidine 
(110uM) and quinine (40uM),   
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Figure 24. Effect of  antimalarials and TSA on expression of p21(WAF1) protein in 
MCF-7 cells. Cells were plated at a density of 1x106 cells/100-mm2 dish. Twelve hours 
after  plating, cells were treated with solvent (distilled H2O, or 0.01%DMSO) or MTS 
IC50 of each compound for 24 h. p21(WAF1) protein levels were measured by 
p21(WAF1) ELISA kit according to the manufacturer’s protocol (Oncogen). Each bar
represents the mean±SEM of  two independent experiments.  
0 5 10 15 20 25
0.00
0.25
0.50
0.75
1.00
Standard p21(WAF1) Concentaration
(units/ml)
Ab
so
rb
an
ce
(49
0n
m
)
H2O  ETOH DMSO MQ PQ AQ HF QA CL QN QL QD TSA
0.00
0.25
0.50
0.75
1.00
1.25
1.50
Compounds
Ab
so
rb
an
ce
(49
0n
m
)
 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25.  Effect of antimalarials on p21(WAF1) protein expression in MCF-7 cells. 
(A) Proteins (50ug) from the cell lysates (same lysate as p21(WAF1) ELISA) were
separated by 12% SDS-polyacrylamide gel electrophoresis and analyzed with Western
blotting using mouse monoclonal antibody for p21(WAF1) as detailed in "Materials and 
Methods". (B) The signal density for each band in Western blot analysis was quantitated by
densitometric analysis. (C) Comparison the results from p21(WAF1) ELISA  and Western
blot analysis. The ‘W’ bar represents the fold increase which is the signal density  in drug
treatment group divided by the signal density in solvent control using Western blot; the ‘E’
bar represents the fold increase which is the absorbance obtained from  drug treatment
group divided by the absorbance obtained from solvent control using p21(WAF1) ELISA .   
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Figure 26. Effect of antimalarials on lipid droplet accumulation in MCF-7 cells.  Cells 
were plated (2x105) in 35-mm2dishes on sterile glass coverslips and grown in DMEM plus 5%
FBS. Cells were treated with solvent (distilled-H20,  or 0.1% ethanol), or MTS IC50 of each 
compound for 48 h; halofantrine (HF) and mefloquine (MQ) were dissolved in  95% ethanol;
other listed antimalarials were dissolved in distilled H2O. Cells were stained with Oil-Red O; 
and counterstained with hematoxylin. The data were presented as percentage of ORO positive
cells in each treatment group. Data are the mean of n=3SER independent experiments in 
which 300 cells per treatment were counted. *, p<0.05; **, p<0.01 for compound versus
control group using ANOVA followed by Bonferroni’s t-tests.  
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primaquine (4uM) and chloroquine (33uM)  also stimulated  lipid accumulation (40% and 30% of 
ORO-positive cells respectively). Quinidine (90uM), quinine (90uM) and primaquine (10uM) induced 
positive ORO staining in 79-89% of MCF-7 cells by 72 h (Johnson and Strobl et al., 1999). Quinidine 
(110uM) treated MCF-7 cells for 72 h show a more intense increase in accumulation of lipid droplets 
compared with 48 h treatment (data not shown). These data suggest that quinidine was the most 
effective compound stimulating lipid droplet accumulation, followed by quinine, primaquine and 
chloroquine. Other quinolines tested were inactive as differentiating agents in this assay (<10% ORO-
positive). 
 
2.2.11. Effect of quinoline antimalarials on apoptosis in MCF-7 cells  
     To determine whether apoptotic cell death may be a contributing factor for antimalarial-induced 
decreases in MTS metabolism, we quantified the release of nucleosomes into the cytoplasm of MCF-7 
cells using a photometric enzyme immunoassay.  Etoposide, a DNA-damaging agent, was used as the 
positive control.  Etoposide causes a double-strand breakage of DNA by forming a complex with the 
enzyme,  topoisomerase II.  Quinolinic acid and quinoline,   compounds that contain only quinoline 
ring structure, did not change nucleosome release as compared with controls (p>0.05). Similarly, 
amodiaquin, mefloquine and primaquine treatments failed to induce apoptosis in MCF-7 cells (Figure 
27). Clearly, quinoline-induced apoptosis was observed with chloroquine, quinidine and halofantrine 
treatment. Induction of apoptosis by these three agents was dependent on their concentrations. A 
statistically significant increase in apoptotic activity was observed after 48 or 72 h of treatment with 
90, 110, 200 and 250uM quinidine in MCF-7 cells compared with control (p<0.05).  These data  are 
consistent with previous reports that quinidine induced apoptosis as evidenced by nuclear 
morphological changes (nuclear collapse) of the MCF-7 cells by 72 h using Hoechst 33342 staining of 
DNA (Wang et al., 1998). Chloroquine-treated cells (33uM) for 48 h exhibited an increase 
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Figure 27.  The apoptotic response to antimalarias in MCF-7 cells. MCF-7 cells (4000 
cells/well in 96-well plate) were grown for 48 h in the presence of increasing concentrations 
of agents. Cells were evaluated for apoptosis by the histone-DNA cell death detection kit as 
described in “Materials and Methods”.  Data are the mean ± SER of three independent 
experiments. One asterisk indicates a p value of <0.05 for compound vs. control using 
ANOVA followed by Bonferroni’s t-tests.  
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Table 2. Enrichment of nucleosome release in the cytoplasm of MCF-7 cells treated with MTS 
IC50 antimalarials, etoposide, and TSA for 48 or 72 h. Cells were lysed, and mono- and 
oligonucleosome levels were determined by photometric enzyme immunoassay using cell death 
detection ELISA. The released nucleosome level of each sample was indicated as the absorbance at 
405 nm. Each experiment was performed in triplicate. The apoptosis enrichment factor of nucleosomes 
released into the cytoplasm for each sample is calculated using the ratio: units of absorbance of sample 
divided by units of absorbance of control group. Data are meanSER of three experiments, each 
performed in triplicate. *, p<0.05 for compound vs. control  using ANOVA followed by Bonferroni’s 
t-tests.  
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Amodiaquin (AQ)                        0.71 ±0.09                   0.86±0.03
 Quinolinic Acid (QA)                   0.98 ± 0.05                  1.01±0.02
  Primaquine (PQ)                           0.92±0.07                     1.17±0.07
  Mefloquine (MQ)                        1.09±0.11                      1.19±0.06
  Quinine (QN)                               1.13±0.09                     1.19±0.07
 Quinidine (QD)                          1.50±0.10                      1.73±0.09
 Chloroquine (CL)                      1.75 ±0.14                      1.82±0.07
 Halofantrine (HL)                      1.2±0.02                        1.1±0.2
 Etoposide (ET 30uM)                2.74±0.13                       1.23±0.20
 Trichostatin A (35nM)              0.96 ±0.06                       0.91±0.05
                                                Apoptosis Enrichment Factor (Mean± SER, N=3)
                                                                   48 h                               72h
  Quinoline (QL)                            1.00±0.06                     1.09±0.03
*
*
**
*
Compounds
(MTS IC50)
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Table 3. A comparison of Ki67, ORO, p21(WAF1) protein, acetylated histone H4 and
apoptotic response in MCF-7 human breast cancer cells treated with MTS IC50
antimalarials. Cells were treated with MTS IC50 of each antimalarial for 48 h. The  Ki67
immunohistochemical assay is index of cell exit to G0. “-”, Ki67 negative cell population is less 
than 10%; “+”, Ki67 negative cell population is more than 20%. Cells accumulating lipid droplets
were determined by Oil-Red O (ORO) assay.  “-”, ORO positive cells are less than 10% or 19%; 
“+”, ORO positive cells are more than 20% and less than 50%; “++”, ORO positive cells are more 
than 50%. P21(WAF1) protein was measured by p21(WAF1) ELISA. “-”, induction of 
p21(WAF1) protein by antimalarial agent treatment for 24 h  was not increased compared with
control cells; “++”, induction of p21(WAF1) protein in treated cells  was increased compared 
with control cells. Acetylated histone H4 was analyzed in MCF-7 cells exposed antimalarials for 
24 h  by Western blot. “+”, agent induced acetylated histone H4; “-”, agent did not cause 
induction of acetylated H4.  Apoptotic response for 72 h treatment in MCF-7 cells  was examined 
using cell death ELISA.  *, p<0.05, treated  versus control group as evaluated using ANOVA
followed by Bonferroni’s t-tests.  
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Table 3. Summary of Antimalarials on G1/G0 Transition, p21(WAF1),
Differentiation, Hyperacetylated Histone H4 and Apoptosis in MCF-7 Cells
Quinolin                NO                          -                              -                                    -                              -                               -
Quinolinic             NO                          -                              -                                    -                              -                                -
     Acid
Amodiaquin        YES                           +                             -                                    -                             +                                -
Chloroquine       YES                            +                             +                                  ++                            +                               *
Halofantrine      YES                             -                             -                                       -                             +                               -
Mefloquine        NO                               -                              -                                      -                               -                             -
Quinidine          YES                             +                            ++                                   ++                              +                            *
Quinine             YES                             +                              +                                     -                               +                             -
Primaquine      YES                              -                              +                                      -                               +                              -
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in the number of soluble nucleosome complexes released (p<0.01) compared with control cells (Figure 
27). However, neither quinine, a quinidine stereoisomer, nor amodiaquin, an analog of chloroquine, 
enhanced the apoptotic response (p>0.05) after 48 or 72 h of treatment compared with control cells.  
     When MCF-7 cells were treated with halofantrine for either 48 or 72 h, nucleosome release 
displayed an increase as the drug concentration was increased from 40 to 100 uM (Figure 27).  
    The enrichment of apoptotic response in MCF-7 cells treated with MTS IC50 concentrations of 
antimalarials for 48 and 72 h are summarized in Table 2. Quinidine (110uM) and chloroquine (33uM)  
induced apoptosis in MCF-7 cells (p<0.05). 
 
2.2.12. Role  of  caspase-3 in quinidine-induced   apoptosis 
    MCF-7 human breast cancer cells are relatively resistant to apoptosis and lack the effector caspase-3 
(Prokop et al., 2000).  The apoptotic response to quinidine was compared in caspase 3-/- MCF-7 cells 
and caspase-3+/+ reconstituted MCF-7 cells. Apoptosis was evaluated on the basis of nucleosome 
release, a characteristic of apoptosis.  Figure 28 shows that the nucleosome release (DNA-histone 
fragmentation) profiles of caspase 3-/- MCF-7 cells as compared with caspase-3+/+ MCF-7 cells after 
treatment with increasing  concentrations of quinidine.  Both cell lines were incubated with quinidine 
for 48 or 72 h. Caspase 3-/- MCF-7 cells, as well as caspase-3+/+ MCF-7 cells, exhibited increased 
DNA-histone fragmentation in response to quindine treatment. Caspase 3-/- MCF-7 cells were less 
sensitive to quinidine in the DNA-histone fragmentation assay, induction of DNA-histone  
fragmentation by quinidine  did not exceed 170% compared to control cells, even in cells treated with 
high concentrations of quinidine for 48 or 72 h. In contrast, caspase-3+/+ MCF-7  cells displayed high 
sensitivity towards quinidine-induced apoptosis,  and incubation with  200 and 250 uM quinidine led to  
a 2-3-fold increase in apoptotic response by 72 h compared with control group.  The 48 h  apoptosis 
response in the quinidine-treated caspase-3-/- MCF-7 cells and  quinidine-treated caspase-3+/+ MCF-7 
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cells  was not different statistically (p>0.05). However, the apoptosis response to quinidine-treated 
caspase-3+/+ MCF-7 cells was significantly increased as compared with caspase-3-/- MCF-7 cells 
(p<0.05) at 72 h. The results indicated that caspase-3 reconstitution sensitized MCF-7 cells to 
quinidine-induced apoptosis. 
 
2.2.13. Role of  Rb on quinidine-induced apoptosis   
 
    Inactivating mutations in the tumor suppressor gene, pRb, have been found not only in 100% of 
retinoblastomas  but  also in many other adult cancers, including breast cancers (Lee  et al., 1988).  Rb 
is necessary to initiate and maintain the cell cycle exit in the differentiation pathway; pRb-mutations in 
cells  prevent cell cycle exit and  block differentiation (Maione  et al., 1997).  MDA-MB-468 human  
breast cancer cells contain mutated pRb (Munster  et al., 2001). The growth of MDA-MB-468 cells 
treated with quinidine was inhibited over a concentration range similar to that for MCF-7 cells. MDA-
MB-468 cells exposed to 110uM quinidine  are not as sensitive as  MCF-7 cells in the MTS assay 
(Figure 29A). There was however no statistically significant difference in DNA-histone fragmentation 
even  in MDA-MB-468 cells exposed to  high concentrations of quinidine for  48  or 72 h  (Figure 29B 
). MDA-MB-468 cells were resistant to quinidine-induced apoptosis. In order to examine the  
hypothesis that wild-type pRb is required for quinidine-induced apoptosis, further  studies are 
necessary to test  whether  pRb reconstituted MDA-MB-468 cells  are more sensitive to quinidine-
induced apoptosis compared to parental MDA-MB-468 cells.  
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Figure 28.  Quinidine induces apoptotic response in caspase-3 (-/-) MCF-7 and 
YAMA (MCF-7, caspase-3 (+/+)) cells. Cells (4000 cells/well in 96-well plate) were 
treated with increasing concentrations of quinidine for 48 or 72 h. The nucleosome levels
were determined by photometric enzyme immunoassay using a cell death detection ELISA 
as described in “Materials and Methods”. The release of nucleosomes into cytoplasm of 
each sample was indicated as the absorbance at 405 nm. Data represent the mean of three
different experiments, each performed in triplicate; bars, SER. * P<0.05, quinidine-treated 
caspase-3(+/+) cells vs. quinidine-treated caspase-3(-/-) cells as evaluated using ANOVA 
followed by Bonferroni’s t-tests.  
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Figure 29.  Effects of quinidine on cell proliferation and apoptosis in MCF-7 and MDA-
MB-468 human breast cancer cells. (A) MCF-7 and MDA-MB-468 cell viability were 
assessed by MTS assay. 4000 cells/well in 96 well plates  were treated with increasing
concentrations of quinidine for 48 h. The percentage of living cells was calculated as 
percentage of control by dividing average absorbances of triplicated drug-treated wells by that 
of control ones.  Data are presented as the mean of three independent experiments, each
performed in quintuplicate; bars, SER. (B) Effect of quinidine on  apoptotic response in
MDA-MB-468 cells. Cells (4000 cells/well in 96-well plate) were treated with increasing 
concentrations of quinidine either for 48  or for 72 h. The released nucleosome levels were
determined by photometric enzyme immunoassay using cell death detection ELISA  as
described in “Materials and Methods”. The released nucleosome levels of each sample was 
indicated as the absorbance at 405 nm. Data represent the mean of three different
experiments, each performed in triplicate. 
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2.3. Discussion 
 
         The enzyme histone deacetylase (HDAC) is a new target for anticancer drug development. TSA 
is an irreversible inhibitor of HDAC activity in cultured mammalian cells and in fractionated cell 
nuclear extracts at low nanomolar concentrations (Kijima et al., 1993). TSA has been shown to arrest 
cells in G1 and G2 phases of the cell cycle, to induce differentiation and apoptosis in cultured cells 
(Yoshida  et al., 1995). G1 arrest by TSA in HeLa cells was accompanied by induction of p21(WAF1) 
(Kim et al., 2000). p21(WAF1) plays a  critical role in TSA-induced growth inhibition because 
HCT116 (p21-/-) cells were resistant to TSA treatment compared with the parental line (p21+/+) (Kim et 
al., 2000). TSA caused a rapid decrease in c-myc gene expression in human lymphoid cell line (Van 
Lint et al., 1996).  Consistent with these literature reports, we observed that TSA affects cell growth, 
p21(WAF1), differentiation, cell cycle progression and apoptosis in MCF-7 cells. The TSA IC50 for 
HDAC activity in HeLa nuclear extract was 8.5 nM.  The MTS IC50 of TSA (35nM) increased 
expression of p21(WAF1) protein in MCF-7 cells. One interesting finding was that MTS IC50 of TSA 
did not trigger apoptosis but caused cell differentiation in MCF-7 cells. Higher concentrations of TSA 
(at least 100 nM) were required for induction of apoptosis in MCF-7 cells. These results demonstrate 
that cellular differentiation could be dissociated  from apoptotic response in MCF-7 cells treated with 
TSA.  
     Although   a variety of structurally unrelated natural inhibitors of HDAC such as butyrate, trapoxin, 
FR901228, and TSA have been isolated (Kijima et al., 1993 and Jung, 2001), the major limitation for 
natural HDAC inhibitors  is that the efficacies are very limited because of its low antiproliferative 
activity and short half life (rapidly metabolized and excreted in vivo)   in blood. On the other hand, 
these inhibitors  such as butyrate ( a natural fatty acid derived from a high-fiber diet)  are weak and 
non-specific inhibition of HDAC activity (Jung, 2001). Therefore, several derivatives of butyrate have 
been studied to improve the rapid metabolism in the body (Pouillart  et al., 1991). TSA, trapoxin and 
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FR901228 were reported to exhibit strong HDAC inhibition in vitro, no in vivo antitumor efficacy has 
been reported, presumably because of instability, low retention, or nonspecific toxicity of the 
compounds in the body. These limitations might be circumvented by development of  antimalarials as 
new HDAC inhibitors,  which  have more favorable pharmacological properties. In this study, we 
summarized a series of experiments that addressed antimalarial induced changes in cell proliferation, 
cell cycle regulation, HDAC activity, histone acetylation and apoptosis in MCF-7 cells. These studies 
also advance the fundamental understanding of antitumor activity by antimalarials, and provide 
knowledge that is essential to developing appropriate anticancer strategies. 
     We demonstrated that antimalarials inhibited cell growth. Inhibition of cell growth by antimalarials 
was examined using the MTS assay and cell counting in MCF-7 cells.  All antimalarials tested 
inhibited MCF-7 cell growth after 48 h treatment. Inhibition of cell growth by these compounds was 
concentration dependent. A comparison of the IC50 values for the nine tested antimalarials indicated 
that mefloquine and primaquine are the most potent agents in MCF-7 cells. In contrast, quinidine is the 
least potent MTS inhibitor in MCF-7 cells.  The variety of MTS IC50 might involve difference in 
composition and orientation of the side-chain structure attached to quinoline rings in each compound. 
Such experimental observations implicate a mitochondria contribution to cell proliferation control.   
     Mitochondria are vital in controlling cell life by at least three general mechanisms, including (1) 
disruption of electron transport, oxidative phosphorylation, and adenosine triphosphate (ATP) 
production; (2) change of the permeability transition pore in the mitochondrial membrane and release 
of proteins that induce cell  apoptosis; (3)  alteration of mitochondria membrane potential  via 
potassium channels.  MTS assay measures the activity of mitochondrial dehydrogenase in cells alive.  
MCF-7 cells were exposed to MTS IC50 of each antimalarial for 2h or 6 h, we only found that 
primaquine-treated-cells for 6 h significantly inhibited the activity of dehydrogenase compared with 
control cells (p<0.05), this result is consistent with previous report that primaquine targeted  succinate 
 119 
dehydrogenase in mitochondria  of malarial parasites (Kokaze, et al., 2000). Cell viability measured by 
trypan blue assay showed that those treatments did not inhibit MCF-7 cell growth within 2 h. These 
results suggest that except for primaquine, antimalarial effects on mitochondrial dehydrogenase reflect 
cell numbers.  In the future, it is necessary to test if antimalarials regulate mitochondrial pore 
transportation and mitochondrial membrane potential, which might help us to understand the 
mechanisms by which antimalarials inhibit cell growth in MCF-7 cells.  
     Theoretically, apoptosis could contribute to the observed antimalarial inhibition of MTS 
metabolism in MCF-7 cells at 48 h. However, in time course experiments, apoptotic cell death was 
detected not earlier than 48 h after quinidine treatment, and maximal yields of apoptosis were induced 
as late as 120 h after treatment (Wang et al., 1998).  Therefore, to determine whether antimalarials 
cause apoptosis and whether apoptosis could contribute to breast cancer cell growth inhibition, the 
yield of nucleosomes released was measured after 48 h treatment of MCF-7 cells with increasing 
concentrations of antimalarials. Apoptosis occurred in MCF-7 cells treated with MTS IC50 of 
quinidine and chloroquine (p<0.05).   Enhanced apoposis in MCF-7 cells treated with halofantrine only 
occurred above 40 uM, but it’s MTS IC50 (11uM) treatment did not increase the rate of apoptosis. 
These data indicate that induction of apoptosis by chloroquine, halofantrine and quinidine was 
concentration dependent and might be a contributor to cell killing (cell death). However, other tested 
antimalarials could not trigger apoptotic cell death pathways to inhibit cell growth.   
      A more intriguing mechanism of quinidine-induced cell growth inhibition was explored. This study 
was performed to gain insight into the molecular mechanism of quinidine-induced cell killing by the 
apoptotic pathway in breast cancer cell lines. Damage to mitochondria can result in release of 
cytochrome c to the cytosol. Cytochrome c causes caspase activation by forming a complex with Apaf-
1 and procaspase-9, leading to activation of casapse-9, which in turn activates procaspase-3, leading to 
DNA cleavage. In this process, Bcl-2 is thought to be involved by preventing the release of 
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cytochrome c from mitochondria thereby inhibition of apoptotic pathway. We previously demonstrated 
that decline of Bcl-2 triggered by quinidine was accompanied by accumulation of cytosolic 
cytochrome c (Zhou and Strobl 2000).  It has been reported that MCF-7 cells lack expression of 
caspase-3 mRNA and protein because of a mutation in the caspase-3 (CPP/YAMA) gene (Kurokawa et 
al., 1999). Abrogation of caspase-3 has been associated with acquired multidrug resistance (Kojima  et 
al, 1998). High concentration of quinidine induced apoptosis in a  caspase-3 independent fashion.  We 
tested whether caspase-3  would  enhance  quinidine-induced apoptosis. 
       MCF-7 (caspase-3 -/-) and MCF-7/YAMA (caspase-3+/+) cells were useful for studying the specific 
role of caspase-3 and caspase-3-dependent signaling in response to quinidine. We characterized the 
apoptotic responses of the MCF-7 cells to quinidine in comparison with MCF-7/YAMA cells. As 
demonstrated by the cell death ELISA, caspase-3 reconstituted MCF-7/YAMA cells showed 
sensitization to apoptosis. Treatment with quinidine between 110 and 250 uM for 72 h exerted more 
dramatic effects on growth inhibition and apoptosis in caspase-3+/+ MCF-7/YAMA cells than did 
quinidine in MCF-7 cells, suggesting caspase-3 defects are one mechanism for chemoresistance to 
quinidine. 
       HDACs regulate histone acetylation by catalyzing the removal of acetyl groups on the NH2-
terminal lysine residues of the core nucleosomal histones.  Modulation of the acetylation status of  core 
histones is involved in the regualtion of the transcriptional activity of  certain genes.  HDAC activity is 
associated with transcriptional repression. Aberrant recruitment of HDAC activity has been associated 
with the development of certain cancers (Lin, et al., 1998), because the cells  are unable to undergo 
differentiation and lead to excess proliferation.  Inhibition of HDAC activity results in the 
accumulation of acetylated histones H2a, H2b, H3, and H4. The result of hyperacetylation of histones 
by HDAC inhibitors is believed to activate a small subset of the genes, which involve cell 
differentiation and apoptosis in cancer cells (Jung,  2001). The HDAC inhibitor sodium butyrate 
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induces hyperacetylation of histone H4, and activates the four genes including actin, adipsin, 
lipoprotein, and adipocyte P2, which mainly modulate differentiation of the preadipocytes into mature 
adipocytes (Toscani, et al., 1990).  Sodium butyrate as well as TSA enhanced p21(WAF1) 
transcriptional activation and   apoptosis  (Lee, et al.,  1996; Archer, et al., 2001). Recently, the 
p21(WAF1) has attracted  more attention,  because the p21 gene appears to be rarely mutated in 
common human  cancer  cells, whereas the p53 gene is frequently mutated. 
        Previously we showed that quinidine induced hyperacetylation of histone H4 without inhibition of 
HDAC activity (Zhou et al., 2000). HDAC1 protein levels were reduced by quinidine treatment, and 
co-treatment with quinidine plus MG-132, a proteasome inhibitor, restored HDAC1 in MCF-7 cells 
within 12 h (Zhou  et al., 2000). We hypothesize that other quinoline antimalarials might share these 
properties. The present study proved that the tested antimalarials do not inhibit HDAC activity in vitro. 
These data are consistent with previous observations that chloroquine, quinidine and quinine did not 
directly inhibit HDAC activity in a cell free assay (Zhou, et al., 2000). Moreover, amodiaquin, 
halofantrine, chloroquine, quinidine, quinine and primaquine stimulated  acetylation of histone H4  in 
MCF-7 cells.  These results indicate that alkylamino-substituted  antimalarial ring might play a role for 
acetylation of histone H4. Further studies are necessary to examine if HDAC1 protein degradation  is 
stimulated  by all antimalarials that induce H4 acetylation in MCF-7 cells.    
     The manner of activation of p21(WAF1) gene expression by antimalarials might contribute to 
understanding  the mechanisms that mediate the anti-proliferative effects of antimalarials.  p21(WAF1) 
expression is usually controlled at the transcriptional level by both p53-dependent and p53-
independent mechanisms. An up-regulation of p21(WAF1) strongly correlates with cell growth 
inhibition, and can force cellular decision  between differentiation and/or cell death. Inhibition of 
p21(WAF1/Cip1) expression through transfection of p21(WAF1/Cip1) antisense oligonucleotides has 
been shown to block growth factor-induced apoptosis of SH-SY5Y neuroblastoma cells (Guo et al., 
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1995). Conversely, transfection of p21(WAF1/Cip1) promotes a variety of cell lines  into 
differentiation  and /or   apoptosis (Jiang  et al., 1995, Pagliacci et al., 1995; Sheikh et al., 1995). These 
lines of evidence indicate that antiproliferative actions of chemotherapeutic agents may be mediated by 
up-regulation of p21(WAF1).  We hypothesize that p21(WAF1) might play a determining role in 
apoptosis and /or differentiation in MCF-7 cells treated with antimalarials. 
      The different effects of quinidine and chloroquine in comparison with  quinine and amodiaquin 
may be related to differences in p21(WAF1) gene expression. Amodiaquin, primaquine and quinine 
did not induce p21(WAF1) expression and apoptosis in MCF-7 cells, but chloroquine and quinidine 
both  elevated p21(WAF1) protein levels and  increased apoptosis  compared to control cells. At the 
chloroquine concentration used in this study, chloroquine exerted a more dramatic effect on MCF-7 
cell cycle arrest and apoptosis than did quinidine.  Our data suggest that p21(WAF1) protein induction 
might be used to predict the ability of  antimalarials to cause apoptosis. 
     Halofantrine (11uM) was not as effective as chloroquine in inducing p21(WAF1) expression and 
apoptosis, but exhibited comparable apoptotic responses at 40uM in MCF-7 cells. Halofantrine  is not 
a quinoline antimalarial, and we concluded that  halofantrine-induced apoptosis might be mediated via 
a different pathway. It is clear that the growth inhibitory effects of antimalarials in breast cancer cells 
as reflected a 50% inhibition of MTS metabolism can be dissociated from apoptosis. Individual agents, 
while all are able to inhibit MTS metabolism, vary with respect to induction of  p21(WAF1) and 
apoptosis.  
       The cell cycle transition into G0 is a prerequisite step for differentiation.  Only amodiaquin, 
chloroquine, quinidine, and quinine at their MTS IC50 led to an increase in the number of cells in the 
G0 phase in MCF-7 cells (Ki67 assay). These data indicate that up-regulation of p21(WAF1) by 
chloroquine and quinidine must  contribute to cell cycle arrest at G0 phase. However, amodiaquin  as 
well as quinine-induced cells into G0 phase are independent of P21(WAF1), which might involve 
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other  cyclin-dependent kinase inhibitors.   Using lipid droplet accumulation measured by ORO 
staining as a marker of mammary cell differentiation, only MTS IC50 of chloroquine, quinidine, 
quinine and primaquine were observed to induce differentiation in MCF-7 cells. We found that  
p21(WAF1) is not determined factor  to contribute to antimalarial-mediated differentiation.   
Furthermore, quinine and primaquine did not exhibit signs of cell apoptosis during the following 48 or 
72 h treatment. Therefore, induction of differentiation by quinine and primaquine was dissociated from 
apoptosis, suggesting that apoptosis is not the only mechanism for inhibition of cell growth by 
antimalarials.  The data also suggested that lipid droplet accumulation is not always a marker of cell 
differentiation, because there was dissociation between the ORO and Ki67 assay, which was observed 
in either amodiaquin or primaquine treatment. In an effort to confirm our conclusion, we need to test 
the milk fat protein expression, another cellular differentiation marker (Munster, et al., 2001), in MCF-
7 cells exposed to amodiaquin and primaquine. 
       In summary, our major conclusion is that quinidine and chloroquine induce growth arrest, cell 
cycle exit, differentiation, hyperacetylation of histone H4, p21(WAF1) and apoptosis in MCF-7 cells. 
Our data is the first report of induction of apoptosis in breast cancer cell lines by the antimalarial 
chloroquine. Quinine (a steric configuration  of quinidine)  as well as  amodiaquin ( an analogue of 
chloroquin) induced cell arrest without apoptosis. We conclude that tertiary amine side chain and its 
configuration may be fundamental requirements for triggering apoptosis  or histone hyperacetylation in 
MCF-7 cells. 
      Although quinidine and chloroquine exerted similar effects on the cell cycle regulatory protein 
p21(WAF1), distinct differences in the kinetics and magnitude of p21(WAF1) protein regulation were 
observed in response to these agents. The activity of chloroquine was significantly more potent than 
that of quinidine. Induction of apoptosis following treatment with halofantrine was not correlated with 
induction of differentiation. These data suggest that differentiation is not obligatory response for 
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apoptosis in MCF-7 cells, implying that antimalarials might trigger multiple cell death pathways. 
Chloroquine is the most potent p21(WAF1) gene regulatory therapy agent and may be of use as a lead 
compound in the design of breast cancer cell apoptotic agents.  
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Appendix 1.  Antimalarials inhibit MTS metabolism  in MCF-7 cells. MCF-7 cells 
were grown in the presence of  increasing concentrations of each compound  for 48 h,
and cell viability was estimated using the MTS assay. These assays were performed 
after 2 h incubation, the MTS activity was then measured at 490 nm using the
microtiter plate reader.  A complete concentration response curve for each compound
is shown. 
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